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ABSTRACT 
 
The primary function of the uterus during pregnancy is to harbour the 
growing fetus in a quiescent environment. Upon maturation of the fetus, the 
uterus generates forceful contractions during labour. Prostaglandins are 
central in the parturition process. PGE2 in particular, is produced in large 
quantities by fetal membranes and possible roles include cervical ripening 
and the stimulation of uterine contractions.  
 
PGE2 exhibits a wide spectrum of physiological actions depending on the 
distribution and subtypes of EP receptors. EP1 and EP3 mediate 
contractions, but there is no consensus about their relative importance. 
Preliminary experiments were undertaken to examine the possible 
expression patterns of EP1 and EP3. The expression data showed there to be 
no significant changes between the localisation in upper or lower segment 
biopsies using both RNA and protein samples. However, there was a labour 
associated change seen in EP3 isoform expression at mRNA level together 
with changes in the protein expression of EP3 in the lower segment using 
immunofluorescence.  Given that the expression studies suggest that it is the 
EP3 receptor, and not the EP1 receptor, that is most important in 
myometrial contractility, I established an in vitro tissue bath to conduct 
functional studies examining contractility in upper and lower segment 
myometrial biopsies. 
 
14 
 
My data demonstrated that stretch of term human myometrium results in 
spontaneous contractions. There was no difference between upper and lower 
segment myometrium, so subsequent experiments were conducted on lower 
segment biopsies. The addition of acetyl salicylic acid (a non-selective COX 
inhibitor) did not completely stop spontaneous contractility but reduced the 
total work done significantly. This could be reversed by add back of PGE2. 
Prostaglandins are therefore significant but not crucial for spontaneous 
contractility.  Both PGE2 and PGF2α increased the total work done 
significantly compared to spontaneous contractions; E2 more so than F2α.  
 
The PGF2α antagonist did not inhibit spontaneous contractions, but did 
inhibit PGF2α induced contractions. The EP1 antagonist did not inhibit 
spontaneous contractions but EP3 antagonist did. These results suggest that 
an EP3 antagonist is a better candidate as a new tocolytic compound 
compared to FP or EP1 antagonist.  
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1.1 Foreword 
 
For the most part of the 20
th
 century, preterm birth, defined as birth at less 
than 37 completed weeks of gestation, was viewed as an unpredictable and 
inevitable fact of life. Medical efforts thus focused on reducing the 
consequences of prematurity, rather than preventing its occurrence. This 
approach resulted in improved neonatal outcomes, but preterm birth remains 
costly both emotionally and financially to the affected infants and their 
families, and adds an economic burden to society.  
 
The EPIPAGE study (Larroque B et al 2008) concluded that one in ten 
children born before 33 weeks gestation had cerebral palsy by the age of 
five years and 40% had some kind of disability. Fig 1.1 illustrates the 
prevalence of cerebral palsy decreasing with increasing gestational
 
age (i.e. 
20% at <27 weeks, 12% at 27 to 28 weeks,
 
8% at 29 to 30 weeks, 7% at 31 
weeks, and 4% at 32 weeks).  
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No. 
Proportion With Cerebral 
Palsy, % P 
 
Total 1954 8.2  
Gestational age at 
birth 
  <.001 
    24–25 wk 62 19.4  
    26 wk 82 22.0  
    27 wk 146 12.3  
    28 wk 191 11.0  
    29 wk 196 8.2  
    30 wk 315 8.3  
    31 wk 424 6.8  
    32 wk 538 4.4  
Infant gender   .10 
    Male 1018 9.2  
    Female 936 7.1  
Plurality   .35 
    Singletons 1339 8.2  
    Twins 529 8.9  
    Triplets and 
quadruplets 
86 4.4  
 
Fig 1.1 Cerebral Palsy Rates According to Gestational Age, Infant 
Gender and Plurality. Cerebral
 
palsy was slightly but not significantly 
more frequent among
 
boys than girls. There was however, no 
difference in cerebral
 
palsy rates according to plurality (Pierre-Yves 
Ancel 2006). 
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Despite diseases of pregnancy and the perinatal period contributing 
considerably to the burden of ill health worldwide, there is an apparent lack 
of initiative by pharmaceutical companies in this field. Fisk et al (2008) 
found just 17 obstetric drugs being developed, compared with 660 for 
cardiovascular disease and 34 for amyotrophic lateral sclerosis. Only 9 of 
the 17 are completely new, and interestingly, these are mostly oxytocin 
antagonists. The authors claim pregnant women are still being treated with 
drugs belonging to a bygone age – magnesium sulphate, nifedipine and 
hydralazine, and that the market must therefore be modified to allow 
obstetric therapeutics to modernise.  
 
A lack of detailed information on the mechanisms of preterm labour has 
hindered the development of novel treatments and preventative measures. 
Therefore, there is a huge unmet need for effective tocolysis. Tocolytics are 
medications used to suppress premature labor (from the Greek tokos, 
childbirth, and lytic, capable of dissolving). The use of a tocolytic drug is 
associated with a prolongation of pregnancy for up to one week, but with no 
significant effect on preterm birth or on perinatal or neonatal morbidity. 
However, if the few days are put to good use, such as completing a course 
of corticosteroids or in utero transfer, tocolysis should be considered.  
 
Indomethacin, a non-selective prostaglandin G/H synthase (PGHS) 
inhibitor, has been used widely in the prevention of preterm birth. King JF 
et al (2005) assessed the effects on maternal, fetal and neonatal outcomes of 
18 
 
COX inhibitors administered as a tocolytic agent to women in preterm 
labour when compared with (i) placebo or no intervention and (ii) other 
tocolytics. The review included data from 13 trials with a total of 713 
women. Indomethacin was used in 10 trials. When compared with placebo, 
COX inhibition (Indomethacin) resulted in a reduction in birth before 37 
weeks' gestation (one trial, 36 women), an increase in gestational age and 
birthweight (two trials, 67 women). A comparison of non-selective COX 
inhibitors versus any COX-2 inhibitor (two trials, 54 women) did not 
demonstrate any differences in maternal or neonatal outcomes. Due to the 
small numbers, all estimates were thought to be imprecise. However, it has 
been its adverse effects, in particular effects on the fetal kidneys and the 
ductus arteriosus, as well as associations with an increased risk of intra-
ventricular haemorrhage (IVH) and necrotizing enterocolitis in the neonate 
that have limited the use of Indomethacin
 
(Seubert De et al 1999). 
 
Nimesulide, a PGHS-2 selective non-steroidal anti-inflammatory drug 
(NSAID) has been used in women at high risk of preterm delivery but is 
also associated with serious fetal side effects (Sawdy RJ, Lye S et al 2003). 
Rofecoxib, a PGHS-2 specific inhibitor is associated with few fetal side 
effects but does not reduce the incidence of preterm delivery and is 
associated with an increased risk of late preterm birth (Groom KM et al 
2005). The authors give a number of possible explanations for the 
disappointing efficacy of prostaglandin synthesis inhibitors including the 
possibility that the inhibition of COX-2 may activate feed-forward 
19 
 
mechanisms, therefore increasing the availability of arachidonic acid or 
directly increasing COX-2 expression. Furthermore, it may be that once the 
COX-2 pathway is inhibited, prostaglandins are synthesised via another 
pathway, such as COX-1. Finally, it is possible that the inhibition of 
prostaglandin synthesis alone is not sufficient to stop the inflammatory 
cascade and therefore the process leading to labour continues via other 
mechanisms. 
 
 
Drugs which inhibit the various PG receptors are now available raising the 
possibility that specific inhibition of PG receptors might be a strategy to 
prevent preterm birth. PG receptors are coupled via G proteins to the second 
messengers cAMP, inositol triphosphate or intracellular calcium release. PG 
receptors have been classified pharmacologically into five main subtypes 
(DP, EP, FP, IP, and TP) one for each of the major classes of PGs i.e. PGD, 
PGE, PGF, prostacyclin and thromboxane respectively. Inhibition of FP has 
been proposed as a strategy to prevent preterm delivery. FP antagonists have 
been shown to inhibit contractions in isolated sheep and human 
myometrium (Olson DM et al 2003) and to open BKCa channels (Doheny 
HC et al 2007). FP antagonists also delay RU486 (Mifepristone) or 
lipopolysaccharide (LPS) induced labour in mice, rat and sheep (Olson DM 
et al 2003, Chollet A et al 2007). However PGE2 is a major PG product of 
fetal membranes and decidua and is thought to act to induce labour partly 
through diffusion to the myometrium. PGE2 binding to myometrium has 
been shown to be 8-10 fold higher than PGF2α (Hoffman HJ et al 1984). 
20 
 
PGE2 binds to its myometrial receptor with higher affinity than does PGF2α 
(Giannopoulos G et al 1985) to its receptor, and PGE2 has been shown to be 
8-10 fold more potent than PGF2α in stimulating myometrial contractions 
(Martin RL et al 2002). Targeting the PGE receptor alone, or in combination 
with other receptor agonists/ antagonists, may therefore be a more effective 
strategy for preventing or delaying preterm delivery. 
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1.2 Clinical Aspects of Preterm Birth 
 
Epidemiology  
Preterm birth refers to birth before 37 completed weeks of gestation. It 
accounts for 6-10% of all births in Western countries and more than two-
thirds of all perinatal deaths. Preterm birth may result from preterm labour, 
spontaneous or induced, or it may be by planned Caesarean section due to 
maternal or fetal complications (Murphy DJ 2007). It is estimated that up to 
30-40% of all cases are induced or elective and the remaining 60-70% occur 
spontaneously (Khan KS et al 2007). Epidemiological studies of preterm 
labour vary in terms of categorization, but generally, labour at <24 weeks is 
considered pre-viable, <28 weeks is extremely preterm, 28-31 weeks very 
preterm and 32-36 weeks mildly preterm (Moutquin JM 2003). Gross 
outcomes after 34 weeks are generally considered to be as good as those 
after 37 weeks gestation (Fig 1.2), though the risk of minor morbidities 
remains (Seubert DE et al 1999). It is the 3-7% of preterm births that occur 
before 34 weeks gestation that account for around 75% of neonatal mortality 
and 50% of long term neurological impairment in children (Khan KS et al 
2007).  
22 
 
 
Gestational 
age  
(weeks) 
Approximate 
survival 
(%) 
Approx 
improvement in 
survival per week 
(%) 
21 0 - 
22 Rare - 
23 25 25 
24 50 25 
25 70 10 
26 80 6 
27 86 5 
28 91 3 
29 94 1 
30 95 1 
31 96 1 
32 97 1 
33 98 1 
34 99 1 
35 99
+
  <1 
36 99
+
  <1 
 
 
 
 
Fig 1.2 Neonatal survival by gestational age and improvement in     
survival by week. Gross outcomes after 34 weeks are generally 
considered to be as good as those after 37 weeks gestation 
(Seubert DE et al 1999). 
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Risk factors for preterm labour include race, age, socio-economic status and 
body mass index (BMI). In the United Kingdom, the risk of preterm birth is 
6% in white Europeans but 10% in Africans or Afro Caribbeans (Murphy 
DJ 2007). Similarly, African-American women are over-represented in rates 
of pre-term birth in the United States. A poorer socio-economic status in 
such groups and other minority groups add environmental causes to the 
plausible genetic causes of preterm birth (i.e. polymorphisms in tumour 
necrosis factor alpha, TNF-α, a pro-inflammatory cytokine) (Macones GA et 
al 2004, Engel SA et al 2005). Other environmental causes include nutrition, 
substance abuse, and psychosocial factors (Murphy DJ 2007).   
 
A strong association with preterm birth in women with a low BMI, poor 
weight gain or excess weight gain and obesity was reported in eight primary 
studies of 122,647 women (Dietz PM et al 2006). Alcohol consumption, 
smoking and cocaine exposure all increase the risk of preterm birth. Dose-
response effects have been described in alcohol consumption in various 
European studies, as well as increased risks from low to moderate and heavy 
smoking (Albertsen et al 2004, Burguet et al 2004). Studies from the United 
States confirm increased risks with cocaine exposure and other psychiatric 
and substance use disorders (Bada HS et al 2005, Kelly RH et al 2002). 
Maternal stress may increase susceptibility to preterm labour. Maternal 
stress may act via a neuroendocrine pathway that activates the maternal-
placental-fetal endocrine systems that promote parturition via an immune 
and/or inflammatory pathway (Wadhwa et al 2001). The complex 
24 
 
interactions between maternal demographics, environmental exposures and 
genetic susceptibility of the mother and fetus require a coordinated research 
approach that brings together the disciplines of epidemiology, laboratory 
based science and clinical trials to offer the best hope of significant 
advances in understanding preterm birth (Murphy DJ 2007) (Fig 1.3). 
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Maternal Demographic 
African-American / Hispanic race 
Low BMI/ excessive weight gain/ loss 
Young maternal age 
  
 Obstetric 
Previous early pregnancy loss 
Previous preterm birth 
Short inter-pregnancy interval (<12 months) 
  
 Medical 
Procedures – LLETZ, amniocentesis 
  
Fetal Male gender 
Multi-fetal pregnancy 
Assisted conception 
  
    
Paternal Older paternal age   
Environmental Infection 
Bacterial vaginosis/ STD’s 
Peridontal infection 
 
Socioeconomic/ Psychosexual 
Social inequality 
Physical violence 
Marital status – single/ cohabitation 
Stressful/ traumatic life events/ depression 
 
Substance use/ toxins 
Excess alcohol - >3 drinks/ day 
Smoking – particularly moderate/ heavy 
Cocaine 
Pollutants – sulphur dioxide/ particulate matter 
 
Nutrition 
Elevated homocysteine/ suboptimal B-12, B-6 
Unbalanced polyunsaturated fatty acids (PUFA) 
 
  
Genetic TNF-a pro-inflammatory cytokine – polymorphisms 
Factor VII/XII – polymorphisms 
  
  
 
        Fig 1.3 Epidemiological and environmental risk factors for preterm 
               labour (Murphy DJ 2007). 
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Causes of Preterm Labour  
Common associations with the onset of preterm labour in the human are 
intrauterine infection, placental abruption, cervical incompetence, premature 
membrane rupture, multiple pregnancy, intrauterine death, fetal and uterine 
abnormalities and chorioamnionitis. However in many cases, there is no 
discernable underlying pathology (Blanks AM et al 2007). Whilst current 
antenatal screening relies on overt clinical and environmental signs and 
symptoms, the clustering of preterm labour within families and recurrence 
in susceptible women presents the case for investigating a possible 
underlying genetic predisposition (Orsi NM et al 2007). 
 
Infection 
There is a strong correlation between infection within the uterus and the 
onset of spontaneous preterm labour. Infection has the potential to activate 
all of the biochemical pathways ultimately leading to cervical ripening and 
uterine contractions; even more so in a cervix that may be shortened or 
weakened. The bacterial species identified in the majority of cases of 
congenital infections is usually identical to that in the maternal lower genital 
tract. Following twin preterm delivery, chorioamnionitis is more common 
and severe in the presenting twin than in the second twin.  These factors all 
suggest that ascending infection from the lower genital tract is the 
commonest mechanism for chorioamnionitis (von Dadelszen P 2003). 
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There is also a recent hypothesis surrounding chronic periodontal infection 
acting as reservoirs for bacterial products and/ or inflammatory mediators 
that play a role in the development of preterm labour. Moderate to severe 
periodontal disease identified in the antenatal period, is associated with an 
increased risk of preterm delivery, as is periodontal disease progression 
(Offenbacher S et al 2006). Several causative pathogens have been 
identified, including the prevotella and pophyromomas species (Urban E et 
al 2006). 
 
Chorioamnionitis 
Chorioamnionitis usually starts with overgrowth of potential pathogens in 
the maternal lower genital tract. This is followed by the presence of the 
organisms in the uterine cavity, particularly in the decidua of the lower 
segment. A localized inflammatory reaction then occurs, leading to 
deciduitis, chorionitis and extension through the amnion into the amniotic 
cavity (Fig 1.4), before finally infection of the fetus itself, by aspiration and 
swallowing of infected amniotic fluid (Romero R et al 1988).   The most 
common microbial isolates from the amniotic cavity of women in preterm 
labour are ureaplasma, urealiticum, fusibacteria and mycoplasma hominis. 
Bacterial vaginosis and trichomonas vaginalis are the two most studied 
organisms associated with preterm birth (Carey JC et al 2000). However, 
screening and treatment of bacterial vaginosis does not seem to influence 
the increased risk of preterm birth (Klebanoff MA et al 2005). 
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Fig 1.4 Chorioamnionitis is defined by the overgrowth of potential pathogens in the 
maternal lower genital tract followed by the presence of the organisms in the 
uterine cavity, particularly in the decidua of the lower segment. A localized 
inflammatory reaction then occurs, leading to deciduitis, chorionitis and extension 
through the amnion into the amniotic cavity before finally infection of the fetus itself 
occurs via aspiration and swallowing of infected amniotic fluid. 
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Abruption 
Placental abruption (Fig 1.5) may lead to the onset of preterm labour. This is 
thought to be through release of thrombin which stimulates myometrial 
contractions by protease activated receptors. This may explain the clinical 
impression that preterm labour associated with chorioamnionitis is often 
rapid whereas that associated with placental abruption is less so, because in 
placental abruption there is no pre-ripening of the uterine cervix.  
Generation of thrombin may also play a role in preterm labour associated 
with chorioamnionitis when it is released as a consequence of decidual 
haemorrhage (Nath CA et al 2007).   
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Fig 1.5 Placental abruption is a complication of pregnancy, wherein the placenta 
has separated from the uterus of the mother. It is the most common pathological 
cause of late pregnancy bleeding. In humans, it refers to the abnormal separation 
after 20 weeks of gestation and prior to birth. 
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Cervical Incompetence 
The cervix maintains the fetus in situ during pregnancy and dilates during 
labour to allow delivery of the baby. This distal component of the uterus is 
primarily composed of connective tissue, of which the majority is collagen 
arranged in fibres and embedded in proteoglycans. There is a small amount 
of smooth muscle (10%) and fibroblast cells (Thomson A et al 2005). Prior 
to and in early labour, the biochemical makeup of the cervix changes, 
making it softer (i.e. ripens) and allowing for dilatation. These biochemical 
changes include a decrease in collagen associated with an increase in 
cervical prostaglandins, pro-inflammatory cytokines, leucocytes, cell 
adhesion molecules and nitric oxide synthase production (Norman JE 2007).  
 
Classical cervical incompetence may be diagnosed in women who have an 
inherent weakness in the cervix or those who have a weakened cervix due to 
previous medical or surgical treatments. Such treatments include mechanical 
cervical dilatation at the time of a termination of pregnancy or surgical 
evacuation of products of conception. During treatment for cervical 
neoplasia, destruction of cervical tissue can occur due to laser treatment or 
biopsies, and in the case of cervical carcinoma, the entire cervix can be 
removed during a trachelectomy. It is now recognized that ‘cervical 
competence’ is a continuum. In a woman with a shortened or damaged 
cervix, bacteria may ascend into the lower segment of the uterus, stimulate 
an inflammatory response, which itself leads to further cervical shortening 
and dilation and so to a ‘vicious cycle’ ending with cervical dilatation and 
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then labour. The same syndrome may be seen where the cervix is of normal 
length but the microbiological load is high. Variations in microbiological 
load may lead to delivery at different gestational ages in different 
pregnancies in the same woman.      
 
Multiple pregnancies 
The rate of preterm labour is high in clinical conditions such as multiple 
pregnancy and polyhydramnios, which are associated with uterine stretch. 
Over distension of the uterus leads to premature up regulation of contraction 
associated proteins which mediate cervical ripening. Studies in sheep have 
shown that stretch increases myometrial the expression of oxytocin 
receptors (OTR) and COX-2 (Wu WX et al 1999); whilst in human models, 
stretch of myometrial and amnion epithelial cells have been shown to 
increase the expression of COX-2 and PGE2 synthesis (Mohan AR et al 
2007). In addition, multiple pregnancies are associated with multiple 
placentae, and therefore an earlier rise in placental CRH concentrations in 
the circulation and subsequently higher rates of preterm birth (Warren WB 
et al 1990). 
 
Genetics 
The most consistent risk factor in identifying preterm labour is a previous 
pregnancy resulting in preterm birth. Most studies quote a risk of 15-18% 
with one previous preterm birth and 28-32% with two previous preterm 
deliveries (Hoffman HJ et al 1984, Carr-Hill RA et al 1985). This has been 
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suggested to be evidence for a genetic basis to preterm labour. However, 
this is problematic, as preterm labour is a complex syndrome involving 
various aetiologies and is masked by multiple confounding environmental 
risk factors. To date, a single gene determinant for preterm labour inherited 
in a conventional Mendelian manner has not been identified. Instead, it is 
generally accepted that susceptibility to preterm labour is governed by 
multigene effects (Orsi NM et al 2007). These effects would regulate 
inflammatory, uteroplacental, endocrine, uterine contraction/ remodeling 
and metabolic pathways (Berhman RE et al 2007).  
 
Matrix metalloproteinases (MMPs) are proteolytic enzymes that cause 
extracellular matrix degradation and are associated with tissue destruction 
and remodeling. In preterm labour, activation is a cytokine-mediated 
inflammatory process, resulting in the rupture of fetal membranes and 
cervical ripening/ dilation. Single nucleotide polymorphisms (SNPs) which 
may regulate MMP expression and activity have been studied. At present, a 
vast number of polymorphisms have been identified in these proteases and 
their tissue inhibitors (Orsi NM et al 2007, Fujimoto T et al 2002). In 
addition to SNPs, complementary analytical approaches such as microarray 
technology and chip arrays have now all been harnessed into determining 
the susceptibility to preterm labour (Esplin MS et al 2005). Once these 
genetic polymorphisms can be clearly related to physiological effects, 
individual predispositions to preterm labour may enable a more targeted 
approach for preventative care. 
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Prediction of Preterm Labour  
As precise disease mechanisms behind preterm birth are not so well 
understood, clinical predictive tests and preventative treatments remain 
limited. However, if women who are at high risk of spontaneous preterm 
birth in early pregnancy can be identified, they may be targeted for more 
intensive antenatal care and prophylactic interventions. A history of 
previous preterm birth, second trimester loss or induced abortion is a non-
invasive, simple, cost-effective method to identify women who may benefit 
from more and intensive screening. Further assessment can be made by the 
use of ultrasonographic cervical length measurement, cervical-vaginal fetal 
fibronectin screening and the detection of uterine contractions. 
 
Fetal fibronectin 
Fetal fibronectin (fFN) is an extracellular matrix found in the decidua 
basalis next to the placental intervillous space. It helps to attach the fetal 
membranes to the uterine decidua and when mechanical or inflammatory 
changes occur, is leaked into the cervico-vaginal fluid. It can be measured 
quantitatively in cervico-vaginal secretions, obtained from the posterior 
fornix when performing an internal examination with a speculum. A 
commercial kit for use on-site has been produced, which gives a positive 
result when concentrations are > 50ng/ml.  
 
fFN is useful in women in threatened preterm labour with not only strong, 
painful contractions, but also in those who are asymptomatic, where a 
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positive test is considered to reflect the consequences of intrauterine 
infection (Shennan A et al 2006). At present, it is widely accepted as a good 
test for excluding preterm birth in those presenting with threatened preterm 
labour due to its strong negative predictive value: 0.5% deliver within 7-10 
days after a negative test (Honest H et al 2002). Furthermore, a positive 
result is associated with the greatest odds ratio for preterm delivery before 
35 weeks gestation (Goldenburg RL et al 2001).  
 
Cervical length measurement  
Ultrasonographic cervical length measurement is a reproducible method of 
assessing the cervix, with little inter- and intra-observer error (Fig 1.6). A 
transvaginal probe is used to obtain the length between the internal and 
external os. The risk of preterm delivery increases exponentially with 
decreasing length, from <1% at 30mm to 80% at 5mm (Heath VC et al 
1988). In women with symptoms of preterm labour, it is estimated that 50% 
of women with a cervical length of less than 15mm deliver within 7 days 
(Nicolaides KH et al 2004).  
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A.  
B.  
 
 
 
Fig.1.6 In ultrasonographic cervical length measurements, a transvaginal 
probe is used to obtain the length between the internal and external os. 
Cervical shortening is demonstrated above by A) a normal cervical canal 
with a closed internal os and B) funneling and shortening of the cervix. 
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Prevention of preterm labour 
 
Cerclage 
If preterm labour does occur secondary to cervical incompetence, inserting a 
suture around the cervix is commonly used to increase mechanical strength 
to the cervix and thereby prevents premature opening in a subsequent 
pregnancy. There are two approaches to the cerclage; abdominal and 
vaginal. In the vaginal approach, the McDonald or Shirodkar methods are 
employed. The McDonald approach involves a suture or tape placed around 
the cervix at the junction between the vagina and the cervix. In the 
Shirodkar suture, the supra-cervical vagina is incised and the bladder 
reflected upwards, allowing the suture to be placed at the cervico-isthmic 
junction. The vaginal epithelium is then repaired (Norman JE 2007). 
 
The most common indication for an abdominal cerclage is a failed vaginal 
cerclage. It requires a transverse incision in the lower abdomen and the 
peritoneum over the cervix and bladder to be deflected down, in order to 
place a suture above the cardinal and uterosacral ligaments. A caesarean 
section is required to deliver the baby and the suture is often not removed, 
unlike in the vaginal cerclage, where removal at 37-38 weeks gestation 
enables vaginal delivery of the baby. Abdominal cervical cerclage may also 
be placed laparoscopically, although published data is currently limited to 
isolated case reports. Although cervical cerclage is widely used in clinical 
practice, there is still limited evidence on its efficacy, whether it is 
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beneficial once cervical shortening has occurred and at what length to 
intervene (Simcox R et al 2007). An international multicentre trial 
conducted by the Medical Research Council (MRC) and Royal College of 
Obstetricians and Gynaecologists (RCOG) recruited 1292 women with a 
history of early delivery or cervical surgery. The findings showed 25 
women needed to be treated to prevent one preterm delivery with no benefit 
to the neonate. However, in women with three or more second trimester 
losses, a cervical suture halved the incidence of preterm delivery prior to 33 
weeks gestation, and in these cases a cervical cerclage was recommended 
(MRC/RCOG 1984). 
 
Progesterone  
Progesterone is a pro-pregnancy hormone and withdrawal in many animal 
models, have shown to lead to an onset of labour. In humans, a functional 
withdrawal is more likely but supplementation of progesterone may 
nevertheless be beneficial in preventing preterm labour. Progesterone has a 
negative effect on many contraction associated proteins and on 
prostaglandin activity (Patel FA et al 1999). In addition, it decreases the 
uterine sensitivity to oxytocin (Grazzini E et al 1998). Placebo controlled 
studies using 100mg progesterone or placebo as a vaginal suppository 
between 24 and 34 weeks, found a significant reduction in preterm delivery 
rates at <37 weeks and <34 weeks in high risk populations (da Fonseca EB 
et al 2003). A study which also examined neonatal outcomes showed a 
reduction in the incidence of birth weight <2500g, necrotizing enterocolitis, 
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intraventricular haemorrhage and the need for supplemental oxygen, but not 
perinatal death or respiratory distress syndrome (Meis PJ 2003). Studies of 
the clinical use of progesterone are ongoing. On the available evidence, it is 
estimated that one in seven high risk women need to be treated with 
progesterone prophylactically to prevent one case of spontaneous preterm 
birth before 34 weeks gestation (Khan KS et al 2007). 
 
Management  
The management of preterm labour may be prophylactic to prevent the onset 
of preterm labour, as discussed above, or reactive once preterm labour has 
started. The primary aims of such measures are for the antenatal 
administration of corticosteroids to the mother and for in utero transfer from 
a peripheral unit to a hospital with neonatal intensive care facilities where 
the outcome for the preterm neonate can be improved significantly.  It is 
therefore essential that a diagnosis of preterm labour should not be 
overlooked.  It is usual to define the onset of labour at term as being when 
regular uterine contractions lead to cervical change or dilatation, but an 
initial diagnosis of preterm labour is usually based upon contractions alone. 
The majority of women diagnosed as being in preterm labour based upon 
contractions alone will go on to deliver at term without intervention. 
Therapy can be more accurately targeted if it is limited to women who are 
either fibronectin positive or have a short cervix. 
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Currently used tocolytics 
Tocolytics may delay delivery for short periods of time in a minority of 
women. Worldwide the recommendation for their use is varied and the 
preferred pharmacological agent differs significantly. They include non 
steroidal anti-inflammatory drugs (NSAIDS), β-adrenergic agonists, 
oxytocin antagonists, calcium channel blockers, magnesium sulphate and 
nitric oxide donors.  
 
β-mimetics, such as Ritodrine and Salbutamol have been used widely as 
tocolytics. They stimulate β2-adrenergic receptors in smooth muscle, which 
act via cAMP to reduce sensitivity and absolute levels of intracellular 
calcium, causing myometrial relaxation (Groom KM 2007). They may be 
successful in delaying preterm delivery for a 48 hour period, but have no 
significant impact on improving neonatal morbidity or mortality. 
Sympathomimetics are associated with significant and severe maternal side 
effects. These include chest pain, dyspnoea, tachycardia, palpitations, 
tremor and hypokalaemia (Giles W et al 2007). 
 
NSAIDS such as Indomethacin, appear to be able to delay delivery for 7-10 
days and reduce rates of delivery <37 weeks gestation (Keirse M 1995). 
They inhibit the cyclo-oxygenase (COX) enzyme responsible for the 
conversion of arachidonic acid to prostaglandins. Their use is limited 
however, by fetal side effects. Premature closure of the ductus arteriosus can 
occur in up to 10-50% of fetuses exposed to indomethacin and is more 
41 
 
prevalent in later gestations (>32 weeks) and if treatment occurs for 
>48hours (Macones GA et al 2001). Other concerns include risks of 
necrotizing enterocolitis, intraventricular haemorrhage and effects on the 
fetal kidneys (Norton ME et al 1993, Kirshon B et al 1991). Selective COX-
2 inhibitors, such as Rofecoxib have been trialed, but unsuccessfully. 
Rofecoxib has reversible negative side effects to the fetus, but does not 
reduce preterm delivery rates <30 weeks and surprisingly, was shown to 
increase deliveries < 37 weeks gestation (Groom KM et al 2005). 
 
Magnesium sulphate, often used in the management of pre-eclampsia, is 
widely used as a tocolytic in North America. It acts as a calcium antagonist 
at the neuromuscular junction (Groom KM 2007). However, randomised 
placebo controlled trials of magnesium sulphate have shown no significant 
short term delay of delivery, increase in birth weight or difference in 
perinatal mortality when compared to placebo (Lyell DJ et al 2007).  With 
limited access to more efficacious tocolytics with fewer side effects, it 
remains the most commonly used tocolytic in the United States.  
 
Nitric oxide donors, such as in the use of GTN patches are popular due to 
the ease of administration and low side effect profile. However, they have 
yet to be proven efficacious in randomised controlled trial and fail on an 
intention-to-treat basis (Duckitt K et al 2002, Bisits A et al 2004).  
 
42 
 
Atosiban marketed as an oxytocin antagonist, is in fact a competitive 
oxytocin and vasopressin antagonist. Oxytocin receptor blockade prevents 
oxytocin induced contractions as well as a reduction in extracellular calcium 
influx and release of calcium from intracellular stores and therefore an 
inhibition of contractility (Groom KM 2007). Administration of Atosiban 
results in a dose dependent inhibition of uterine contractility and oxytocin 
mediated prostaglandin release. In pregnant women, Atosiban is 46-48% 
plasma protein bound and appears to have limited cross-over into the fetal 
circulation. 
 
The randomised controlled trials comparing Atosiban to beta mimetics show 
similar efficacy, but a superior safety profile in terms of maternal adverse 
outcomes (Marsal K 2001, Moutquin JM et al 2001). There is still some 
uncertainty over the preferred use of Atosiban over Nifedipine (a calcium 
channel blocker) for tocolysis. In the absence of a direct comparison 
between the two tocolytics, adjusted indirect comparisons with Nifedipine 
have shown to significantly reduce rates of respiratory distress syndrome 
(RDS) in the neonate but do not significantly decrease time to delivery 
(Coomaraswamy A et al 2003).  
 
Nifedipine is a calcium channel blocker originally developed almost fifty 
years ago as a treatment for angina pectoris. It is now used widely for the 
treatment of coronary heart disease, hypertension and chronic stable angina. 
The effect of calcium channel blockers in relaxing the myometrium has also 
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been known for several years. Calcium channel blockers exert their effect 
by binding to L-type channels and reducing intracellular levels of calcium. 
This blocks the transmembrane influx of calcium ions into muscle cells. By 
binding to intracellular calcium binding proteins, Nifedipine is therefore, 
able to block the flow of extracellular calcium into myometrial cells and in 
this way relaxes the myometrial smooth muscle. 
 
There have been no trials comparing Nifedipine with placebo, but it has 
been compared against a beta sympathomimetic, Ritodrine in a number of 
randomized controlled trials. Nifedipine is preferable as it has a better side 
effect profile and demonstrated a reduction in the number of preterm births 
within seven days of starting treatment (King et al 2003). The RCOG 
support the use of Nifedipine for tocolysis, but it is not licensed for use in 
United Kingdom and there is no standardized administration dose or regime. 
 
Corticosteroids  
Corticosteroids in the management of preterm labour can be administered as 
a single course of either betamethasone or dexamethasone.  If given, 
between 24 and 34 weeks gestation and up to 7 days before preterm 
delivery, it has a significant effect upon neonatal morbidity and mortality.  
This is principally due to a significant reduction in respiratory distress 
syndrome (RDS) and intraventricular haemorrhage (IVH) rates.  Antenatal 
corticosteroids have a receptor mediator effect on all of the components of 
the surfactant system in type-2 pneumocytes.  They also however have 
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effects on the structural development of the lungs, lead to accelerated 
maturation of the fetal intestine, have effects upon the myocardium and on 
catecholamine responsiveness. This may explain the reduced incidences of 
necrotising enterocolitis and intraventricular haemorrhage seen in extremely 
preterm infants that appear to be independent of the effect upon RDS 
(Roberts D et al 2006). The long term consequences of recurrent exposure to 
high dose steroids, suggesting adverse effects on development and 
behaviour, has lead to a policy of limiting administration of antenatal 
corticosteroids to a single course if possible. 
 
Antibiotics  
The administration of antibiotics to prevent preterm labour is variable in 
clinical practice. There have been many studies of different antibiotics and 
routes of administration, but the results vary according to the pre-existing 
risk of the population.  Research has focused on bacterial vaginosis (BV), 
where the normal vaginal lactobacilli are replaced by a mixed flora with 
high concentrations of anaerobic bacteria. Other organisms known to 
increase the risk of adverse outcomes are Trichomonas vaginalis and 
Mycoplasma hominis (Leitich H et al 2003). The effects of metronidazole, 
erythromycin and clindomycin have been shown in some studies to improve 
success in symptomatic women, women at high risk and those with a 
positive fFN (Hauth JC et al 1995, Lamont RF et al 2003). However, other 
studies have shown an increase in rate of delivery before 37 weeks gestation 
with the use of metronidazole; perhaps, due to the eradication of normal 
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flora and hence the proliferation of harmful bacteria (Klebanoff MA et al 
2001). A recent meta-analysis looking at prophylactic antibiotics for the 
prevention of preterm birth in women at risk included 17 trials and found no 
reduction in preterm birth irrespective of the criteria used to assess risk (i.e. 
abnormal vaginal flora, previous preterm birth or positive fetal fibronectin 
status). This was regardless of the antimicrobial agent used or the 
gestational age at time of treatment (Simcox R et al 2007). Similarly, the 
ORACLE II study showed no evidence of benefit of antibiotics in 
established preterm labour. A later analysis of the longer term outcomes of 
the ORACLE II babies shows that antibiotic use increases the risk of 
cerebral palsy (Kenyon S et al 2008). 
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Preterm prelabour rupture of membranes 
Preterm prelabour rupture of membranes (PPROM) occurs in approximately 
2% of all pregnancies and accounts for up to one third of preterm deliveries.  
The consequence of PPROM is as many as 50% cases deliver within a 
week, 75% within two weeks and 85% within a month.  As with preterm 
labour, postnatal survival following PPROM is directly related to 
gestational age at delivery and birth weight. The retention of amniotic fluid 
within the uterus is associated with a better outcome. The management of 
PPROM continues to be controversial, however many obstetricians will 
favour conservative management in preterm premature rupture of 
membranes before 34 weeks and would induce labour relatively early in 
women whose membrane rupture occurs subsequent to 34 weeks.  
 
Conservative management should include clinical surveillance for signs of 
chorioamnionitis including regular recording of maternal temperature and 
heart rate and cardiotocography. A rising white cell count or a rising CRP 
level may indicate the development of chorioamnionitis, though neither of 
these is highly specific. Lower genital tract swabs are routinely taken and 
positive cultures for potential pathogens are useful in directing antibiotic 
therapy for both the mother and the preterm neonate. The potential benefits 
of tocolytic drugs do not apply in the majority of cases of PPROM and 
neither do the few case reports of amnio infusion. 
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1.3  The Anatomy of the Uterus and Cervix 
 
The uterus is the organ of gestation, receiving the fertilised egg in its cavity, 
retaining and supporting it during the development of the fetus and 
becoming the principal agent in its expulsion at the time of parturition. It is 
situated in the pelvis between the bladder and rectum; it is retained in 
position by the round and broad ligaments on each side and the cardinal and 
uterosacral ligaments below (Fig 1.7). The non-gravid uterus measures 
about 7cm in length, 4cm in breadth at the fundus and almost 2cm in 
thickness. 
 
The uterus consists of two parts: (1) the corpus, with its broad upper 
extremity, the fundus and (2) the cervix, which is partly above the vagina 
and partly in the vagina. The division between the corpus and the cervix is 
indicated externally by a slight constriction, and by the reflection of the 
peritoneum from the anterior surface of the uterus on to the bladder, and 
internally by a narrowing of the canal, the internal os. 
 
The uterus is a muscular organ which increases in fibrous and elastic tissue 
during pregnancy, together with the stretching and hypertrophy of 
myometrial cells. These smooth muscle cells form functional contractile 
bundles, covered in connective tissue and interspersed with an extensive 
vasculature. In addition, there is a varied population of leucocytes that 
secrete cytokines, including macrophages, neutrophils, large granular 
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lymphocytes and other descendents of T-cells as reviewed by Terzidou 
(2007). Single myocytes may produce force in any direction thereby 
allowing the uterus to generate a multidirectional force as a whole. During 
active labour, the fundal region contracts to expedite delivery, whilst the 
lower segment relaxes to allow passage of the fetal head. A fundo- cervico 
gradient has been described with regards to contractile receptor proteins 
such as oxytocin and connexin-43 (Fuchs AR et al 1984, Sparey C et al 
1999).  
 
The cervix comprises the lower, cylindrical portion of the uterus, containing 
collagen fibrils, elastic connective tissue, blood vessels and some muscle 
fibres. Macrophages and neutrophils infiltrate the cervix at term inducing 
cytokines and also producing enzymes capable of digesting extracellular 
matrix proteins, necessary for cervical ripening. 
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Fig 1.7 Diagram demonstrating the anatomy of the non-pregnant uterus. 
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1.4 The Endocrinology and Biochemistry of Labour  
 
There is a challenge in predicting, diagnosing and managing preterm labour, 
because despite extensive research, the mechanisms that control the length 
of human pregnancy and signal the onset of labour have not yet been fully 
determined. Throughout pregnancy the uterine cervix needs to remain firm 
and closed whilst the body of the uterus grows by hypertrophy and 
hyperplasia whilst remaining quiescent. During pregnancy, ‘pro-pregnancy’ 
factors such as progesterone and prostacyclin inhibit myometrial 
contractility. Parturition involves a synchronisation of changes in the 
structure of the cervix, myometrial activity manifesting as painful uterine 
contractions and ruptured fetal membranes leading to cervical dilation and 
effacement. At the end of the pregnancy, ‘pro-labour’ factors begin to 
mediate remodeling of the cervix and the uterus is stimulated to begin co-
coordinated contractions (Terzidou V 2007). It has been suggested that 
labour results from the activation of a ‘cassette of contraction-associated 
proteins’ (CAPs), which include gap junction proteins, oxytocin and 
prostanoid receptors, enzymes for prostaglandin synthesis and cell signaling 
proteins (Lye et al 1994). However, the term ‘labour associated proteins’ 
may be more appropriate since these are also responsible for activating fetal 
membrane prostaglandin and cytokine production, as well as cervical 
remodeling and ripening (Fig 1.8). 
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Fig 1.8 Factors influencing preterm labour. 
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Inflammation 
Inflammation is now considered to be integral to the pathophysiology 
behind preterm labour. Microarray and suppression subtractive 
hybridisation studies have demonstrated an up regulation of a vast number 
of pro-inflammatory genes in fetal membranes, myometrium and the cervix 
with the onset of labour (Charpigny G et al 2003). This is demonstrated by 
an influx of inflammatory cells into the uterus and increased expression of 
pro-inflammatory cytokines (Young A et al 2002). The transcription factor, 
nuclear factor-kappa B (NF-κB) which is activated within the uterus at the 
time of labour, regulates a number of inflammatory factors, including IL-6, 
IL-8 and COX-2 (which leads to prostaglandin synthesis) (Allport VC et al 
2003). At term, this inflammatory-type response may be triggered by the 
maturing fetal lung which produces increased surfactant lipid and protein 
(i.e. surfactant protein A, SP-A). This is associated with the activation of 
macrophages in the amniotic fluid and an increased inflammatory response 
in the uterus (Condon JC et al 2004).  
 
Corticotrophin-releasing hormone 
Corticotrophin-releasing hormone (CRH) is a peptide produced by the 
hypothalamus in response to stress. CRH is also expressed abundantly in the 
placenta and in maternal serum CRH has been shown to rise in the second 
half of pregnancy, peak during labour and rapidly decline postpartum. In 
patients who have gone on to deliver prematurely, elevated levels of CRH in 
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the maternal circulation have been identified as early as 18 weeks of 
gestation (McLean M et al 1995).  The exponential curve depicting the CRH 
increase is shifted to the left in women who subsequently deliver preterm 
and to the right in women who deliver post dates. This suggests that CRH 
production is linked to a placental clock (Fig 1.9) which determines the 
length of gestation (Smith R, Van Helden D et al 2007). The implications of 
this clinically could mean that maternal plasma CRH concentrations could 
help indentify women at high risk of preterm delivery and CRH antagonists 
may be useful in preventing preterm labour (Smith R, Nicholson RC et al 
2007). 
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Fig 1.9 Pathway for action of placental corticotrophin releasing hormone on 
parturition. 
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Progesterone 
Progesterone is thought to act during pregnancy to inhibit labour-associated 
gene expression and inhibit contractions. Unlike most mammalian 
counterparts, human circulating progesterone levels and progesterone 
receptors (PR) in the myometrium do not fall with the onset of labour. 
However, clinically the administration of a PR antagonist RU486 can be 
used to ripen the cervix and induce labour. In the absence of a demonstrable 
fall in progesterone concentrations, it may be possible that a ‘functional 
progesterone withdrawal’ precedes the onset of labour. This could be due to 
changes in the different PR levels or isoforms (Mesiano S et al 2002), 
specifically a reduction in myometrial responsiveness to progesterone by an 
increased expression of PR-A relative to PR-B (Pieber D et al 2001). It may 
also be due to the interaction between NF-κB and PR or changes in PR co-
activator and co-repressor expression. 
 
NF-κB 
NF-κB is a cytokine-inducible transcription factor activated in response to 
infection and pro-inflammatory cytokines which regulates many pro-
inflammatory and labour associated genes (Baeuerle PA et al 1996). In most 
cells, NF-κB exists in an inactive form in the cytoplasm, bound to an 
inhibitory protein, such as IκBα. Three distinct NF-κB signaling pathways 
have been identified to date (Terzidou V 2007). Labour is associated with an 
increase in the baseline level of NF-κB DNA binding and transcriptional 
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activity in the human amnion and because NF-κB down regulates 
progesterone receptor function, it seems to be related to a ‘functional 
progesterone withdrawal’ in the human myometrium (Chapman NR et al 
2004). 
 
Prostaglandins and cyclo-oxygenases 
It is now established that prostaglandins (PGs) play a central and essential 
role in the biochemistry of human labour
 
(Albertsen K et al 2004). 
Prostaglandins of the E and F series stimulate uterine contractions 
throughout pregnancy and are used clinically to induce first and second 
trimester abortion and labour at term. There is increased synthesis of PGs by 
intrauterine tissues, particularly the fetal membranes, at the time of labour 
which is associated with a rise in the concentrations of PGs and PG 
metabolites in amniotic fluid and maternal plasma (Slater DM et al 1995, 
1999).   
 
Prostaglandins belong to the eicosanoid family of lipid mediators and are 
derived from arachidonic acid (AA) found in membrane phospholipids of 
the cell. The prostaglandin biosynthetic pathway (Fig 1.10) can be divided 
into three main stages. The initial step involves the mobilization of AA from 
membrane phospholipids by the action of phopholipase enzymes. In the 
second stage, the free AA is converted to an unstable prostaglandin 
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intermediate, in a two-step reaction catalysed by the cyclo-oxygenase 
(COX) enzymes. This reaction involves the conversion of AA to 
hydroperoxy endoperoxide (PGG2), which in turn undergoes reduction to 
form hydroxyl endoperoxide (PGH2). Since no pathway exists for the re-
conversion PGH2 to AA, the COX enzymes mediate the committing step of 
prostaglandin biosynthesis. Finally, the PGH2 intermediate is converted to 
the terminal prostaglandins PGE2, PGF2α, PGD2, prostacyclin (PGI2) and 
thromboxane by their respective synthase enzymes (Kniss DA 1999). 
 
In addition to mediating the committing step, the COX enzymes are also 
thought to catalyse the principle rate-limiting step of prostaglandin 
biosynthesis (Slater DM et al 1995). The COX enzymes exist as two main 
isoforms: the constitutively expressed COX-1 and the inducible COX-2 
isoenzyme. In human labour, there is substantial evidence for the greater 
importance of the COX-2 enzyme rather than COX-1. Amnion is a major 
source of prostaglandins and displays a marked increase in the synthesis of 
PGE2 with labour onset and stretch. This is associated with the selective 
induction of COX-2 expression (Slater DM et al 1999). Similarly, a labour 
associated increase in COX activity in the chorion is attributed to the 
upregulation of COX-2, but not COX-1 expression. Upregulation of COX-2 
expression in lower segment myometrium has been shown to occur with 
advancing gestational age and was maximal just prior to labour at term, 
suggesting a role for myometrial COX-2 in the early phases of the 
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parturition cascade (Romero R et al 1988).  
 
 
               Arachidonic Acid 
  Epoxygenases       Lipoxygenases 
   
       Cyclogenase reaction     COX-1 
          COX-2 
HETES                           Epoxides 
Leukotrienes 
               PGG2 
          Peroxidase reaction       COX-1 
                         COX-2 
 
        PGI synthase            PGH2  TXA synthase 
PGI2                TXA2 
           
          
               TXB2 
PGD                          PGF       PGF  
synthase                        synthase       isomerase 
         
 PGD2               PGF2α        PGE2 
 
 
Fig 1.10 Biosynthetic pathway for the formation of eicosanoids derived from 
arachidonic acid. 
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In relation to the role of prostaglandins in preterm labour, they are products 
of the inflammatory process and also play a key role in the mechanisms of 
infection associated premature labour. Infection increases prostaglandin 
production by amnion, chorion and decidua through the activity of bacterial 
products, cytokines, growth factors and other inflammatory mediators 
(Gomez R et al 1995, Kelly RW 2002). Concentrations of PGE2 and PGF2α 
in amniotic fluid are significantly higher in women with preterm labour who 
have confirmed chorioamnionitis than women with preterm labour and no 
evidence of infection (Romero R et al 1988). In addition, higher levels of 
prostaglandins are produced from the amnion of patients with histologic 
chorioamnionitis compared to amnion from patients without documented 
chorioamnionitis (Lopez Bernal A et al 1987). 
 
Interleukin 8 
IL-8 acts a chemokine and is produced by human endometrium, chorio-
decidua and myometrium. IL-8 plays an important role in cervical ripening, 
probably aids in the formation of the lower segment of the uterus in late 
pregnancy and mediates the influx of inflammatory mediators, specifically 
leukocytes, seen in the myometrium during labour (Mohan AR et al 2004). 
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Oxytocin 
Oxytocin (OT) is a nonapeptide produced by the posterior pituitary, known 
to have a potent contractile activity on the pregnant uterus. However, it does 
not seem to be essential for normal parturition as there is no increase in 
circulating oxytocin in the mother or fetus with the onset or during labour. 
Moreover, normal parturition has been observed in cases of clinical pituitary 
gland dysfunction (Phelan JP et al 1978). However, the expression of the 
oxytocin receptor (OTR) does increase in the pregnant uterus. An up-
regulation by two orders of magnitude has been demonstrated leading to a 
strong increase in sensitivity towards OT (Soloff MS 1975). Comparable 
increases in OTR mRNA concentrations in the myometrium are associated 
with this up-regulation of OT- binding sites (Jeng YL et al 2003). Post 
delivery, myometrial OT-binding sites rapidly decrease, whereas OTR 
expression remains high in the mammary gland throughout lactation (Soloff 
MS et al 1979).  
 
In many animals, OTR is regulated by changes in steroid hormone 
concentrations (Soloff MS 1975). In humans, the lack of marked changes in 
oestrogen concentrations or progesterone withdrawal suggests that OTR has 
a more complex regulation (Gimpl G et al 2001). Further relationships in the 
OTR system have been demonstrated, in particular with prostaglandins. 
Treatment with naproxen, a prostaglandin-synthesis inhibitor, resulted in a 
dramatic decrease in OTR in the rat uterus at term. Administration of PGF2α 
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restored the increase in OTR, implying the possibility of a positive feedback 
loop between prostaglandins and OTR (Chan WY 1980). 
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1.5 Myometrial Contractility 
 
Irrespective of the aetiology of preterm labour, the underlying mechanism 
by which the myometrium contracts is thought to be the same. During 
pregnancy, the uterus maintains a quiescent environment, whereas at the 
point of fetal maturity, it generates forceful contractions, observed to 
originate from the fundus to expel the conceptus, whilst the lower segment 
remains relaxed in order to allow the fetal head to pass.  
 
The basic functional unit of the myometrium is the smooth muscle cell, 
which is in turn, arranged into bundles of approximately 300+/- 100µm in 
diameter. Each bundle is surrounded by connective tissue interspersed with 
microvasculature. The bundles are further organized into fasiculi, which are 
covered by a dense collagen matrix and the major vasculature of the 
myometrium (Young RC et al 1999). This therefore enables the uterus to 
generate an expulsive force dependent on the orientation of these fibres 
relative to the cervix. Uterine contractions are then initiated by the 
propagation of action potentials within these defined vectors of muscle 
bundles (Blanks AM et al 2007). The intracellular basis for contraction is via 
the cyclical attachment and detachment of cross-bridges between myosin 
and actin filaments, triggered via activation of the regulatory 20kDa chain 
of myosin molecules. Myosin light chain is activated by phosphorylation by 
myosin light chain kinase, which in turn, is activated by calmodulin (Word 
RA et al 1993). It is through the actions of calmodulin, that during an action 
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potential, the calcium influx can be connected with a contraction; a process 
known as excitation-contraction coupling (Blanks AM et al 2007). Once the 
uterus has been activated, the myometrium is susceptible to stimulation by a 
number of different agonists, primarily prostaglandins and oxytocin.  
 
Myometrial cells maintain ionic gradients across the plasma membrane and 
with the change of membrane permeability to calcium, sodium, chloride and 
potassium, generate an action potential. In human myometrium, the 
depolarising current is mainly mediated by calcium (via L-type calcium 
channels) and repolarisation is mainly carried by potassium (Shmygol A et 
al 2007). The process of contractility in myometrial smooth muscle is ATP- 
dependent and is proportional to the activity ratio of myosin light chain 
kinase (MLCK) to myosin phosphotase (MLCP). It is by altering the 
activity ratio of MLCK to MLCP that oxytocin and PGF2α increase the 
sensitivity of the myometrium to calcium (Woodcock NA et al 2004, 2006). 
This sensitisation occurs after contraction has been initiated and is mediated 
by a decrease in MLCP activity, which in turn is controlled by several 
processes such as the activation of G-protein rhoA or the activation of CPI-
17 by protein kinase C (Kitazawa T et al 2000). 
 
In order to propagate action potentials, myometrial cells are connected by 
connexins (gap junction proteins) through which ions and some cellular 
metabolites can pass. In the myometrium, an increase in the number of gap 
junctions has been observed in both term and preterm labour, as well as 
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improved intracellular conductance and metabolic communication (Garfield 
RE et al 1988, Sims SM et al 1982). Connexin-43 (CX-43) appears to be the 
most important in gap junction formation as it is present in all gap junction 
plaques and a delay in parturition has been observed in CX-43 knockout 
mice (Kilarski WM et al 2001, Döring B et al 2006). Furthermore, in human 
myometrium, the expression of CX-43 was found to be the greatest at the 
fundus implicating a stronger contractile potential to the upper segment 
(Sparey C et al 1999). 
 
Physiological stimulation once myometrial activation has occurred is 
principally via prostaglandins and oxytocin. Oxytocin increases contraction 
frequency, duration and force by increasing the frequency of depolarisation, 
sensitising the contractile machinery to calcium and prolonging the duration 
of the action potential plateau (Nakao K et al 1997, Woodcock NA et al 
2004). G-protein coupled oxytocin receptors release G-protein subunits 
(from Gαi) which leads to the activation of phospholipase C, which is 
responsible for the mobilisation of calcium from sarcoplasmic reticular 
stores via inositol 1, 4, 5,-triphosphate (InsP3). This is sufficient to open L-
type calcium channels and allow full depolarisation (Phaneuf S et al 1996).  
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Prostaglandin receptors 
Prostaglandins were originally thought to interact directly with the cell 
membrane, thereby altering its characteristics and modulating cell 
physiology. However, their different activity profiles and generation of 
second messengers, principally cAMP, phosphatidylinositol turnover and 
Ca
2+
, suggests that they interact with discrete receptors and that different 
receptors exist for each PG. Coleman et al (1994) used specific antagonists 
to further characterize these receptors pharmacologically. They classified 
the receptors as one each for PGs, D2, F2α, I2 and TXA2, as DP, FP, IP and 
TP and four for PGE2 as EP1-4. The first receptor that was isolated and 
cloned was the TP receptor. This is a G protein linked member of the 
rhodopsin family of receptors with seven transmembrane domains. 
Subsequently, homolgy screening using mouse cDNA libraries led to the 
identification of the structures of all eight receptors, each encoded by a 
different gene (Narumiya S et al 1999).  
 
More recently, several splice variants have been identified for human EP3 
(eight isoforms), sheep and bovine FP (two isoforms), rat EP1 (two 
isoforms) and human TP (two isoforms) (Pierce KL et al 1998). They vary 
largely in their cytoplasmic C-termonal regions where coupling with G 
protein occurs. The amino acid sequences have been fully described for rat 
and sheep. There is only 20% homology between amino acid sequences of 
various receptors within a species, but 79-89% homology exists between 
like receptors of different species (Olson DM 2003). 
66 
 
 
The EP receptor family is composed of four distinct subtypes; EP2 and EP4 
stimulate adenylate cyclase and cAMP production via the stimulatory 
subunit Gs, resulting in muscle relaxation (Fig. 1.11), whereas EP1 and EP3 
mediate muscle contraction through increased phosphinositol turnover and 
calcium mobilisation, or decrease adenylate cyclase and cAMP levels, 
respectively (Coleman RA et al 1994).  
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Figure 1.11 Signaling pathways for EP1 and EP2/4.  EP1 is coupled to Gq and 
upon PGE2 binding there is a signal cascade that results in activation of 
phospholipase C (PLC) and mobilisation of intracellular calcium (Ca
2+
) stores.  EP2 
and EP4 are coupled with Gs.  PGE2 binding results in activation of adenylyl 
cyclase (AC) and cyclic adenomonophosphate (cAMP).  This leads to activation of 
protein kinase A (PKA) and subsequent phosphorylation (P) of CREB, which leads 
to up-regulation of the cyclic AMP response element (CRE) (Kandola M 2008).  
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The EP3 receptor is unique in that eight different receptor isoforms have 
been identified, encoded by nine transcripts: EP3-I(1a), EP3-I(1b), EP3-II, 
EP3-III, EP3-IV, EP3-V, EP3-VI, EP3-c and EP3-f generated by alternative 
splicing at the carboxy terminal tail (Schmid et al 1995, Kotani et al 1997, 
2000). As the carboxy terminal end of the receptor is important for 
mediating G protein coupling, changes in this region appear to alter the 
coupling affinity. EP3 is mainly coupled to Gi and hence towards a 
contractile phenotype. However, splice variants EP3-II and EP3-IV may 
couple Gs and/or Gq leading to different cellular responses (Namba et al 
1993, Kotani et al 1995) (Fig. 1.12). 
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Figure 1.12.  Signaling pathways for EP3 isoforms.  A. EP3 is coupled to Gq and 
upon PGE2 binding there is a signal cascade that results in activation of 
phospholipase C (PLC) and mobilisation of intracellular calcium (Ca
2+
) stores.  B. 
EP3 is coupled to Gi.  PGE2 binding causes inhibition of adenylyl cyclase (AC) and 
therefore mobilisation of intracellular Ca
2+
.  C. EP3 is coupled with Gs.  PGE2 
binding results in activation of AC and cyclic adenomonophosphate (cAMP).  This 
leads to activation of protein kinase A (PKA) and subsequent phosphorylation (P) 
of CREB, which leads to up-regulation of the cyclic AMP response element (CRE) 
(Kandola M 2008). 
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PGF2α similar to PGE2 is a potent stimulator of myometrial tissue 
(Parkington HC et al 1999), but there is no consensus on how. The FP 
receptor is coupled to Gαq class of G-proteins and therefore stimulation of 
PLC should release InsP3 (Carrasco MP et al 1996). However this has not 
been consistently demonstrated in freshly isolated myometrial strips from 
pregnant patients (Schery MP et al 1988). What has been demonstrated 
however is the calcium sensitising effect of PGF2α is rho-kinase mediated. 
This is preceded by depolarisation and results in a large increase in 
intracellular calcium (Woodcock NA et al 2006). This effect may aid 
delivery by producing a strong contraction, whilst increasing the recovery 
period between contractions to reduce the risk of hypoxia and fetal distress 
(Parkington HC et al 1999). 
 
There is little consistency in the literature concerning the myometrial 
expression of the two ‘contractile’ receptors EP1 or EP3 (Fig 1.13). Astle et 
al (2007) found that EP1 expression is upregulated in human lower segment 
myometrium at the time of labour but found no change in upper segment 
myometrium. Conversely, Smith GC et al (2001) found that EP1 expression 
was greatest in baboon upper segment myometrium and found no changes 
with labour. Grigsby PL et al (2006) found that human myometrial EP1 
expression increases with gestational age in both upper and lower segment 
but found no regional differences. Ma X et al (1999) found no expression of 
EP1 at all in sheep myometrium.  
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With respect to EP3, Astle et al (2007) found greater expression in upper 
segment, but mostly in vascular smooth muscle cells not myocytes. 
Moreover, down regulation of EP3 with labour was observed. Smith GC et 
al (2001) found EP3 expression to be greater in upper segment myometrium 
with no labour associated changes. Grigsby PL et al (2006) found no 
regional differences and no changes in association with labour.  Leonhardt 
A et al (2003) found that there was no expression of EP3 in human pregnant 
myometrium but did find expression of EP1 and so concluded that PGE 
leads to contractions via EP1. Ma X et al (1999) found a labour associated 
increase in EP3 expression in sheep myometrium. 
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Fig 1.13 Summary of the literature findings with regards to myometrial expression 
and changes of the ‘contractile’ PG receptors, EP-1 and EP-3 with regards to their 
presence in the upper segment (US) and lower segment (LS) and changes with 
gestation and labour. 
 
 
 
Author Myometrial 
sample 
EP 
receptor 
Presence 
in US 
Presence 
in LS 
Changes 
with 
gestation 
Changes 
with 
labour 
Astle Human 1 + +  ↑ LS 
3 ++ +  ↓ 
Smith Baboon 1 ++ +  Nil 
3 ++ +  Nil 
Grigsby Sheep 1 + + ↑  
3 + +  Nil 
Ma Sheep 1 - -   
3 + +  ↑ 
Leonhardt Human 1 + +   
3 - -   
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1.6 Hypothesis and Objectives 
 
Currently, there are no effective tocolytics free of side-effects. PGE2 
receptors represent potential targets, but which EP should be targeted would 
depend upon expression and functional data. EP1 and EP3 are said to 
mediate contractions, but there is no consensus about their relative 
importance. There is little consistency in the data regarding EP expression 
in myometrium during pregnancy. To examine the roles of EP1 and EP3 in 
causing myometrial contractility, we undertook expression studies and 
contractility studies.  Mandeep Kandola, a scientist in our group, examined 
the expression of EP receptors by Western blotting, immunofluoresence and 
QRT-PCR in the upper and lower segment myometrial samples that I had 
obtained from the pregnant, non-labouring women, at term, at elective 
Caesarean sections and from labouring women at emergency Caesarean 
sections. 
 
Expression of EP-R protein on the cell surface 
In order to study the changes that occur between quiescence and active 
labour, as defined by contractions, immunohistochemistry combined with 
immunofluorescence is often used to decipher the expression of proteins at a 
particular time point. Immunohistochemistry refers to the process of 
detecting antigens (e.g. proteins) in cells of a tissue section by exploiting the 
principle of antibodies binding specifically to antigens in biological tissues. 
Immunofluroscence uses the specificity of antibodies to their antigen to 
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target fluorescent dyes to specific biomolecule targets within a cell, and 
therefore allows visualisation of the distribution of the target molecule 
through the sample. The advantage of this method is that it is quantitative as 
opposed to qualitative. Therefore, the higher the immunofluroscence seen, 
the more receptor is present. To quantitatively assess the presence of 
proteins, Western blotting is also used. 
 
Using these two techniques we were able to assess PGE2 receptor protein 
expression in the upper and lower segment myometrium.  In the lower 
segment, EP1 expression in the lower segment (LS) was less than that in the 
upper segment (US). There were no significant differences between labour 
plus (L+) and labour minus (L-) samples (Fig. 1.14). Similarly, there were 
no significant changes observed in EP3 expression in both US and LS, as 
well as L+ and L- myometrial biopsies (Fig. 1.15). 
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Figure 1.14.  No labour associated change of EP1 receptor 
protein expression in human myometrium at term. EP1 receptor 
expression was compared in matched lower segment (LS) and 
upper (US) segments of term laboring (L+) and term non-labouring 
(L-) myometrium. Whole cell extracts were subjected to Western 
blotting and blots were scanned for densitometric analysis. Values 
were normalised using the housekeeping gene GAPDH. Results 
are the mean of 3-6 samples and not significant (p>0.05). 
Representative Western blots are shown. 
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Figure 1.15.  No labour associated change of EP3 receptor 
protein expression in human myometrium at term. EP3 receptor 
expression was compared in matched lower (LS) and upper (US) 
segments of term laboring (L+) and term non-labouring (L-) 
myometrium. Whole cell extracts were subjected to Western blotting 
and blots were scanned for densitometric analysis. Values were 
normalised using the housekeeping gene GAPDH. Results are the 
mean of 3-6 samples and the differences were not significant 
(p>0.05). Representative western blots are shown. 
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Both the EP1 and EP3 receptors were demonstrated in all the sample groups 
using immunofluorescence. Co-localisation with the smooth muscle alpha-
actin stain confirmed their presence in the smooth muscle. In the upper 
segment, EP1 receptor protein was not significantly affected by labour 
status in the US. There was however, significant change in the labouring 
lower segment versus the non-labour samples (p=0.05) (Fig.1.16). Similarly 
the EP3 receptor increased significantly in the labouring LS myometrium 
(p=0.02) (Fig. 1.17). 
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Figure 1.16.  EP1 receptors are significantly upregulated in the lower 
segment of the labouring myometrium. EP1 receptor expression was 
measured in matched lower (LS) and upper (US) segments of term labouring 
(L+) and non-labouring (L-) myometrium. Tissue was paraffin-embedded and (A) 
the specificity of the antibody determined using immunohistochemistry with 
polyclonal EP1 antibodies. Replacement of anti-EP1 antibodies with pre-immune 
IgG and saturation of anti-EP1 antibodies with blocking peptides were used as 
negative controls. (B) Immunofluorescent analysis for EP1 was visualized with 
red-fluorescent Alexa Fluor 594 dye and α-actin was visualized with green 
fluorescent Alexa Fluor 488 dye. Nuclei were stained with DAPI. (C) Intensity of 
receptor expression was analysed by measuring levels of fluorescence and 
applying statistical analyses. These graphs represent the intensity of expression 
of each PGE2 receptor in the cytosol of myocytes (n=3).  
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Figure 1.17.  EP3 receptors are significantly upregulated in the lower 
segment of the labouring myometrium. EP3 receptor expression was 
measured in matched lower (LS) and upper (US) segments of term labouring 
(L+) and non-labouring (L-) myometrium. Tissue was paraffin-embedded and (A) 
the specificity of the antibody determined using immunohistochemistry with 
polyclonal EP3 antibodies. Replacement of anti-EP3 antibodies with pre-immune 
IgG and saturation of anti-EP3 antibodies with blocking peptides were used as 
negative controls. (B) Immunofluorescent analysis for EP3 was visualized with 
red-fluorescent Alexa Fluor 594 dye and α-actin was visualized with green 
fluorescent Alexa Fluor 488 dye. Nuclei were stained with DAPI. (C) Intensity of 
receptor expression was analysed by measuring levels of fluorescence and 
applying statistical analyses. These graphs represent the intensity of expression 
of each PGE2 receptor in the cytosol of myocytes (n=3).  
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A fundo- cervico gradient has been described with regards to contractile 
receptor proteins such as oxytocin and connexin-43 (Fuchs AR et al 1984, 
Sparey C et al 1999). However, there is no clear consensus between EP1 
and EP3 localisation in labouring and non-labouring myometrium, as 
illustrated by Fig.1.13. 
  
In summary, the expression data showed there to be no significant changes 
between the localisation in upper or lower segment biopsies using both 
RNA and protein samples.  However, there was a labour associated change 
seen with EP1 and EP3 in the lower segment using immunofluorescence. 
Furthermore, there were changes in the intracellular localisation of the 
receptors; EP1 showed a significant increase in the nuclei of labouring 
upper and lower segment myometrial biopsies. EP3, however, was primarily 
in the cytoplasm.  To demonstrate the significance of this, I established an in 
vitro tissue bath to conduct functional studies examining contractility in 
upper and lower segment myometrial biopsies. 
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2.0 Materials and Methods 
 
The research was conducted at the Institute for Reproductive and 
Developmental Biology, Imperial College at the Hammersmith Hospital 
site. Collection of tissue was approved by the local Ethics Committee and 
written informed consent was given by all subjects. Experiments were 
performed on human myometrial biopsies taken at elective caesarean 
section at term. All caesarean sections were conducted at Queen Charlotte’s 
Hospital and samples stored in at least 10mls of Eagle’s medium. In each 
case, a single lower segment biopsy of about 2 x 2 x 1cm was taken from 
the upper margin of the lower segment incision (Fig 2.1). In the laboratory, 
this was divided into 8 strips approximately 1 x 0.5 x 0.5cm (Fig 2.2) and 
mounted within the 8 individual baths in the myograph. 
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Fig 2.1 Myometrial sample taken from the lower segment of human 
myometrium at elective caesarean sections at term. Only women having 
elective caesarean sections for breech or a previous caesarean section were 
consented. Following the delivery of the fetus and placenta, myometrial 
tissue would be cut from the upper edge of the uterine scar. This did not 
cause additional bleeding or add significant time to the operation.
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In order to sample upper segment myometrial tissue, four biopsies 
measuring 0.5 x 0.5 x 0.5cm (Fig 2.2), were taken by inserting a 
cervical punch biopsy (Fig 2.3) through the lower segment incision 
and obtaining tissue from the fundus. Limitations to this methodology 
include a degree of damage to the upper segment myometrium by the 
cervical punch biopsy apparatus as well as some endometrial lining 
being included in the biopsy. Pre-labour samples were taken at 
elective caesarean section for indications such as breech presentation, 
previous caesarean section or maternal request. In-labour samples 
were taken from women with spontaneous onset of labour who 
reached at least 4cm cervical dilatation who had not received either 
prostaglandin or oxytocin. All samples were used within three hours 
of collection. 
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Fig 2.2 Strips of myometrial tissue; lower segment (on the left) divided  
from a larger sample, as illustrated in Fig 2.1, and upper segment (on 
the right), obtained using the cervical punch biopsy.
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Fig 2.3 A cervical punch biopsy used for obtaining upper segment myometrium at 
caesarean sections at term.
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2.1 Contractility Studies  
 
Contractility studies were undertaken using a Myograph 800MS (Danish 
Myo Technology) (Fig.2.4), which can be used to study small myometrial 
samples of about 0.5cm in length. The Myograph 800MS with smaller organ 
baths (capacity 4mls) was ideal for the smaller upper segment biopsies. 
However, smaller baths are also more sensitive to changes in temperature, 
pH, volume and oxygenation.  For example, concentrations of substrates 
that were added to the bath had to be diluted into smaller volumes so as to 
not upset the bath by huge changes in total volume.  
 
 
Myometrial samples were mounted between metal clasps attached to 
isotonic tension transducers in individual organ baths filled with 4ml of 
modified Krebs solution; the concentrate was kindly provided by Glaxo 
Smith Kline, Harlow, and made up in the lab to the following specifications: 
NaCl 119mmol/l, CaCl2 16mmol/l, NaHCO3 25mmol/l, KCl 14.7mmol/l, 
KH2PO3 1.18mmol/l, MgSO4 1.17mmol/l, Glucose 5.5mmol/l to a pH 7.4 at 
a temperature of 37
o
C. This was then perfused with a 95% O2/ 5% CO2 
ratio gas mixture. Transducers were calibrated once a month by balancing 
known 2 g weights on inverted scales that applied force onto the 
transducers. This was used as a reference in the Chart software version 5.0 
and later upgraded to 5.2 (PowerLab, ADI Instruments). 
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Fig 2.4 The Myograph 800MS with smaller organ baths (capacity 4mls) which was 
ideal for the smaller upper segment biopsies. The muscle strip was placed 
between two clamps and dissection forceps were used to attach the strips in order 
to reduce handling of the myometrium and minimise damage. The two clamps, 
when pulled apart, recorded the tension produced by the myometrial strip through 
a transducer. This was connected directly to the computer software which 
processed the data. 
88 
 
Preliminary experiments showed that to measure both spontaneous and 
stimulated contractions, myometrial samples needed to be placed under 4g 
of tension (Fig 2.5). The choice of setting the initial tension to 4g was based 
on the tension that the most number of strips responded to (i.e. 80%). As the 
experiment progressed, the tension would settle to 2g. This is consistent 
with current published data. A baseline period of one hour was observed and 
experiments were only conducted on strips that contracted spontaneously 
within 90 min of the set-up and had achieved a minimum peak tension of 1g 
(Fig 2.6). The average life span for the tissue strip was for a total of 90 
minutes following the initial 60 minutes of incubation. Most experiments 
were conducted on spontaneous contractions, unless otherwise stated. The 
contractions had been stable for a minimum of 15 minutes before additional 
agents were added in 15 minute intervals. All the data obtained; rate per 
contraction, peak tension per contraction, duration per contraction, work 
done per contraction and total work done was recorded using the Chart 
software and processed by a PC based Excel program. 
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Tension (g) No. of strips contracting at 1hr (%) 
0 0 
2 25 
4 80 
6 50 
8 40 
 
 
Fig 2.5 Preliminary experiments showed that stretch is essential for 
spontaneous contractility in myometrial strips. When using the Myograph 
800MS, myometrial samples needed to be under a minimum of 4g 
tension to achieve the maximum of strips to contract. 
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Fig 2.6 A real time image of spontaneous contractions resulting from the 
stretch of a non-labouring, lower segment myometrial strip after an hour. 
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2.2 Drug Assessment 
 
The first series of experiments compared upper segment with lower segment 
myometrium. The initial step was to compare spontaneous contractions, in 
both the upper and lower segment. The next experiment explored the effect 
of increasing concentrations of PGE2 on spontaneous contractions. 
Cumulative concentrations of PGE2 (10
-10
, 10
-9
, 10
-8
, 10
-7
, 10
-6
 mol/l) were 
added to the organ baths at 15 minute intervals. The effect of increasing the 
concentration of PGE2 on myometrial contractility was assessed by 
calculating an average of the preceding 15 minute interval as a ratio of the 
average in the first 15 minutes of spontaneous contractions.  
 
A novel OT antagonist, GW796679X with a molecular weight (MW) of 484 
and a dissociation constant (Ki) of 1.5nM was provided by Glaxo Smith 
Kline, and compared against equimolar concentrations of a known OT 
antagonist, Atosiban. Cumulative concentrations of OT (10
-10
,10
-9
,10
-8
,10
-7
, 
10
-6
 mol/l Syntocinon) were then added to the organ baths at 15 minute 
intervals. Similar to the first design and in following experiments, the effect 
of the antagonists and/or agonists on myometrial contractility was assessed 
by calculating an average of the preceding 15 minute interval as a ratio of 
the average in the first 15 minutes of spontaneous contractions. 
 
Other compounds that were tested include acetyl-salicylic acid (ASA) 
(Sigma-Aldrich, Poole, UK), PGF2α, a novel FP antagonist (FPA) donated 
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by Serono and two novel EP1 and EP3 antagonists donated by Glaxo Smith 
Kline (GSK). FPA has a Ki of 6nM for the prostaglandin F receptor (FP) 
and is 10-100 folds selective for FP compared with other prostanoid 
receptors.  
 
The EP1 (ZD6416) and EP3 (L798106) antagonists are both small 
molecules. ZD6416 shows fpKi for EP1 8.4 +/-0.6 and for EP3 6.3 +/-0.4. 
L798106 shows fpKi for EP1 6.0+/-0.4 and for EP3 7.9 +/-0.4. Schild 
analysis has shown that each is a competitive antagonist devoid of agonist 
activity up to 10µM. The effective concentrations of each against their 
respective receptors are therefore 2 orders of magnitude apart. A 
concentration of 100nM of each antagonist was calculated to ensure 
complete and specific inhibition of the relevant receptor.  
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2.3 Data Analysis 
 
Data was calculated by taking the average of each 15 minute interval and 
expressing it as a ratio of the average in the first 15 minutes of spontaneous 
contractions. In the case, where there were no spontaneous contractions 
after the baseline one hour, due to the pre-incubation of an antagonist, the 
data was not normalized and will be stated as such.  
 
The first parameter analysed was rate per contraction. This looked at the 
number of contractions that occurred within the set time period in seconds 
(in the majority of cases, 900s = 15 minutes). The second parameter was the 
peak tension, i.e. the maximum tension achieved by each strip in grams. The 
third parameter was duration per contraction. This illustrated how long a 
contraction lasted in seconds. The final parameters were the average work 
done by each contraction and the total work done by all the contractions 
within a set time frame. This was a calculation of the area under the curve 
[height (gram) x width (second) x ½]. Statistical significance was 
determined by ANOVA, where the p value was less than 0.05 (Fig 2.7). 
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Duration per 
contraction (s)
Peak tension 
(g)
Work done per 
contraction (g.s)
Rate per contraction = Number of contractions within a time frame
Peak tension (g) = Maximum tension achieved by the contraction
Duration per contraction (s) = Time take per contraction from start to finish
Work done per contraction  (g x s) = Energy generated by each contraction (area under 
the curve)
Total work done = Energy generated by all the contractions within the specified time 
frame (900s)
 
Fig 2.7 An illustration of the parameters used to calculate the results: rate 
per contraction, peak tension per contraction, duration per contraction, work 
done per contraction and total work done. 
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3.1 Contractility in upper versus lower segment myometrium  
 
Two series of experiments were undertaken to compare contractility 
between upper and lower segment myometrium. In the first series matched 
(i.e. from the same patient) upper and lower segment biopsies from term 
non-laboured myometrium were established in the myograph and the 
absolute contractility parameters were compared (Fig 3.1). There were no 
differences between lower and upper segment samples in the duration taken 
for contractions to begin, or in any of the contraction parameters: rate per 
contraction, peak tension per contraction, the duration per contraction, work 
done per contraction and therefore in the total work done (p=0.149) at 90 
minutes.  
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A    B  
C    D  
 
 E        
 
 
Fig 3.1 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from upper and lower segment, non-labouring myometrium at term over 90 
mins. No significant difference in any of the parameters was demonstrated 
between matched upper and lower segment human myometrium (n=8) as 
demonstrated by the total work done at 90 mins (p=0.149). 
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3.2 Contractility in prostaglandin stimulated upper and lower 
segment myometrium  
 
In the second series of experiments comparing upper and lower segment 
myometrium, PGE2 was added at concentrations of 10
-10
, 10
-9
, 10
-8
, 10
-7
 and 
10
-6
 at 15 minute intervals, after the baseline period of spontaneous 
contractions had been established (Fig 3.2). The effect of PGE2 upon 
contractility was expressed as a ratio to spontaneous contracting 
myometrium. 
 
PGE2 caused a dose dependent increase in contractility in both upper and 
lower segment myometrium at concentrations above 10
-8 
(p=0.042) versus 
spontaneously contracting myometrium. However, there was no difference 
in the total work done between PGE2 stimulated upper and lower segment 
myometrium (p=0.177). 
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A  B  
C  D  
 
             E  
 
Fig 3.2 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from upper and lower segment, non-labouring myometrium at term with 
increasing concentrations of PGE2 added over 90 mins. No significant difference in 
any of the parameters was demonstrated between matched upper and lower 
segment human myometrium (n=6) as demonstrated by the total work done at 
concentrations of 10
-6 
(p=0.177). However, PGE2 caused a dose dependent 
increase in contractility in both upper and lower segment myometrium at 
concentrations above 10
-8 
(p=0.042) versus spontaneously contracting 
myometrium.  
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3.3 Discussion of contractility in upper and lower segment 
myometrium 
 
The body of the uterus comprises of two parts, the uterine corpus (upper 
segment) and the isthmus (lower segment). A concept of functional 
differences has been proposed both physiologically and at a protein 
expression level. Various studies have shown differences in mRNA 
expression between upper and lower segment, leading to criticism that 
experiments on the lower segment may not truly represent the uterine body. 
A fundal to cervical gradient has been described with regards to 
prostaglandin receptors by Wikland et al (1983), to oxytocin receptors by 
Fuchs et al (1984) and splicing factors SF2/ ASF by Pollard et al (2000). 
 
This study was initiated in the first instance to identify, if any, a difference 
between upper and lower segment, term, myometrial tissue. This study and 
that of Lucas et al (2000) are the only studies to have directly compared 
upper and lower segment myometrium from the same patient. Some studies 
have suggested that PGE2 might contract the upper but have no effect, or 
relax the lower segment (Gordon-Wright et al 1980). It is possible that 
differences between studies may be due to the differences in the site from 
which the myometrial biopsy is taken. If a lower segment myometrial 
sample is taken from very close to the cervix then there may be more 
cervical than myometrial smooth muscle cells present and the effect of 
PGE2 may be different.  
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The first set of data demonstrated the effect of PGE2 on both upper and 
lower segment myometrium, and agrees with similar data from Lucas at el 
(2000). There were no differences in spontaneous contractility between 
upper and lower segment myometrium (p=0.149). Furthermore, PGE2 
consistently caused contractions of upper and lower segment tissue and 
again there was no difference between the corpus and isthmus (p=0.177). In 
addition, our own expression studies of EP1 and EP3 expression also show 
no difference in upper versus lower segment myometrium. Recent evidence 
using trans-abdominal magneto-myographic recording has demonstrated the 
synchronisation of electrical burst activities, which are essential for 
effective uterine contractions, are identified not only at the fundus but over 
the entire uterus as well (Eswaran et al 2005). Furthermore, no specific pace 
maker activity seems to have been identified over any specific area of the 
uterus. This would correlate with anatomical findings by Lucas et al (2000) 
and Word et al (1993) that demonstrate similar proportions of smooth 
muscle in the uterine muscle in both upper (65.4%) segment and lower 
(69.8%) segment myometrium. Given the ease to obtain lower segment 
myometrium and my findings, subsequent experiments used only lower 
segment myometrium. 
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4.1 The effect of PGE2 on spontaneously contracting lower 
segment myometrium. 
 
Fig 4.1 illustrates the effect of PGE2 on spontaneously contracting human 
lower segment uterine tissue taken in real time from the myograph. 
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Fig 4.1 A pictorial representation of increasing concentrations of PGE2 on an 
isolated myometrial strip taken from the lower segment of non-labouring 
myometrium at 15 min intervals.  
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PGE2 added at concentrations of 10
-10
, 10
-9
, 10
-8
, 10
-7
, 10
-6
 at 15 minute 
intervals, after the baseline period of spontaneous contractions had been 
established caused a dose dependent increase in contractility in 
concentrations above 10
-8 
versus spontaneously contracting myometrium 
(p=0.042). The effect of PGE2 upon contractility was expressed as a ratio to 
spontaneous contractility in the preceding 15 minutes and then as a 
percentage of maximally stimulated contractility (Fig 4.2).  
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A     B  
C     D  
     E  
                  
Fig 4.2 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of PGE2 added over 75 mins. PGE2 caused a dose dependent 
increase in contractility in lower segment myometrium at concentrations over 10
-8 
(p=0.042) versus spontaneously contracting myometrium as demonstrated by the 
total work done (n=7). 
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4.2 The effect of PGF2α on spontaneously contracting lower 
segment myometrium. 
 
Fig 4.3 illustrates the effect of PGF2α on spontaneously contracting human 
lower segment uterine tissue taken in real time from the myograph. 
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Fig 4.3 A pictorial representation of increasing concentrations of PGF2α on 
an isolated myometrial strip taken from the lower segment of non-labouring 
myometrium at 15 min intervals. 
Increasing concentrations of PGF2 α over time (s) 
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There was a statistically significant increase in the total work done when 
PGF2α at a concentration of 10
-7 
was added to spontaneously contracting 
lower segment myometrium (p=0.014), (Fig 4.4). It appears to be less potent 
than PGE2 as a higher concentration of PGF2α is required to significantly 
increase the total work done by spontaneously contracting myometrium.  
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A   B  
C   D  
 
    E           
                        
Fig 4.4 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of PGF2α added over 75 mins. PGF2α caused a dose dependent 
increase in contractility in lower segment myometrium at concentrations over 10
-7 
(p=0.014) versus spontaneously contracting myometrium as demonstrated by the 
total work done (n=10). 
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4.3 The effect of acetyl salicylic acid (ASA) on spontaneously 
contracting lower segment myometrium and PGE2 induced 
contractions 
 
Pre-incubation of lower segment human myometrial strips with ASA, an 
inhibitor of both COX-1 and COX-2, for one hour prior to the experiment 
led to a 3-fold reduction in peak tension and therefore overall work done, 
from 15 minutes into the experiment (t15) (p=0.022). Due to the design of 
the experiment (i.e. pre-incubation of the myometrium), the data could not 
be normalised and is represented as such (Fig 4.5). 
108 
 
A      B  
C      D  
 
     E  
               
Fig 4.5 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with a pre-incubation 
of 1μl of ASA for 60 mins prior to the experiment commencing (n= 10). This led to a 
3-fold reduction in peak tension and therefore a significant reduction in the total 
work done from 15 minutes into the experiment (p=0.022). 
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In the next experiment, PGE2 was added in increasing concentrations from 
10
-10
 to 10
-6
 to myometrium pre-treated with ASA, and the effects were 
compared with spontaneously contracting myometrium and ASA pre-treated 
myometrium (Fig 4.6). The addition of PGE2 returned peak tension and 
overall work done per contraction to control values. 
 
As above, inhibition of contractility was again demonstrated by ASA, as the 
total work done by the controls was significantly greater (p=0.007). The 
total work done by the ASA pre-treated strips that had the addition of PGE2, 
was significantly greater than the strips with ASA alone (p=0.001) but not 
the controls (p=0.311).  
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A      B  
 
C      D  
 
       E   
Fig 4.6 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of PGE2 added to pre-incubated strips of myometrium of ASA for an 
hour, against strips pre-incubated with ASA alone and against controls (n=7). 
There was statistical significance in the reduction of total work done by the strips 
with ASA alone in comparison to the controls (p=0.007) and those strips that had 
increasing concentrations of PGE2 (p=0.001). There was no statistical difference 
between the controls and the ASA pre-incubated strips with the addition of PGE2 
(p=0.311). 
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4.4 Discussion of the effects of PGE2, PGF2α and ASA on 
contractility. 
 
The second set of experiments quantified the effect of known agonists, 
PGE2 and PGF2α.  There was a statistically significant increase in the total 
work done by the myometrial strips following the addition of either agent. 
This was observed at concentrations above 10
-8
 (p=0.042) and 10
-7
 
(p=0.014) for PGE2 and PGF2α respectively. This confirms results of 
previous studies which demonstrated that PGE2 binds to myometrium 8-10 
fold more than PGF2α (Hoffman HJ et al 1984). Furthermore, Giannopoulos 
G et al (1985) have demonstrated that PGE2 binds to its myometrial receptor 
with a higher affinity than PGF2α, and Martin RL et al (1995) have  shown 
PGE2 to be 8-10 fold more potent than PGF2α in stimulating myometrial 
contractions. 
 
Incubation of strips with acetyl salicylic acid (ASA) an inhibitor of both 
COX-1 and COX-2 for one hour prior to the experiment led to a 3-fold 
reduction in peak tension and therefore overall work done, from 15 minutes 
into the experiment (p=0.022).  
 
Furthermore, the addition of PGE2 (from concentrations of 10
-10
) to pre-
incubated myometrium containing ASA, returned peak tension and overall 
work done per contraction to normal values. The total work done by the 
ASA pre-treated strips that had the addition of PGE2, was significantly 
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greater than the strips with ASA alone (p=0.01) but not the controls 
(p=0.311). ASA (as in the previous experiment) again demonstrated 
inhibition of contractility against spontaneously contracting myometrium 
(p=0.07). These data suggest that stretch and synthesis of prostaglandins is 
essential for spontaneous contractility in human myometrial strips and that 
PGE2 is more important in stimulating contractions than PGF2α. 
 
Having established that the synthesis of PGs is key for spontaneous 
contractility, further experiments were conducted to discover a method of 
blocking the effects. An established approach has been to block the pathway 
in the synthesis of PGs, essentially by blocking the enzyme pathways (i.e. 
COX), but NSAIDs (e.g. Rofecoxib, Indomethacin) are associated with 
harmful side effects for both mother and fetus (Groom KM et al 2005, 
Sawdy RJ, Lye S et al 2003). An alternative approach would be to allow the 
production of PGs, but to specifically block the receptors instead. 
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5.1 The effect of an EP1 antagonist, ZD6416 upon spontaneous 
and PGE2 stimulated contractions. 
 
Three series of experiments were undertaken to assess the effects of the EP1 
antagonist ZD6416 upon spontaneous and PGE2 stimulated contractions. In 
the first series, ZD6416 was added at increasing concentrations of 10, 100 
and 1000nM (i.e. the optimal concentration and one order of magnitude 
either side) to spontaneously contracting myometrial strips at 15 minute 
intervals (Fig 5.1). The EP1 antagonist had no effect upon any individual 
aspect of contractility or upon total work done at any of the above 
concentrations (p=0.117, p=0.103, p=0119) respectively.  
114 
 
A   B  
C   D  
 
 
E  
         
Fig 5.1 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of ZD6416 added over 45 mins (n=6). No significant difference in 
any of the parameters was demonstrated as illustrated by the total work done at 
the following concentrations, 10nM, 100nM or 1000nM (p=0.117, p=0.103, p=0119) 
respectively. 
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In the second series of experiments, ZD6416 at 100nM was added to the 
Kreb’s solution at the start of the experiment (Fig 5.2). Pre-incubation with 
ZD6416 at 100nM for an hour did not inhibit any aspect of contractility nor 
the total work done (p=0.104). Due to the nature of the experiment (i.e. pre-
incubation of the myometrium), the data could not be normalised and is 
represented as such. 
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A    B  
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Fig 5.2 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with a pre-incubation 
of 100nM of ZD6416 for 60 mins prior to the experiment commencing (n= 14). Pre-
incubation with ZD6416 did not inhibit any aspect of contractility including the total 
work done up to 45 mins following the pre-incubation period (p=0.104). 
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In the third series of experiments involving ZD6416, 100nM was added to 
the Kreb’s solution after the baseline period of spontaneous contractions had 
been established. Following which, at fifteen minute intervals, increasing 
concentrations of PGE2 was added at concentrations from 10
-10 
to 10
-6 
(Fig 
5.3). 
 
 
As seen previously PGE2 caused a dose dependent increase in contractility 
at concentrations above 10
-8
 (p=0.048), but there was no inhibitory effect of 
ZD6416 at this concentration of PGE2 (p=0.899). 
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            E  
 
Fig 5.3 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of PGE2 added over 75 mins to spontaneously contracting 
myometrial strips and to strips pre-incubated with a 100nM of ZD6416 (n=7). PGE2 
caused a dose dependent increase in contractility in lower segment myometrium at 
concentrations over 10
-8 
(p=0.048) versus spontaneously contracting myometrium 
as demonstrated by the total work done. There was no inhibitory effect of ZD6416 
at this concentration of PGE2 (p=0.899). 
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5.2 The effect of an EP3 antagonist, L798106 upon spontaneous 
and PGE2 stimulated contractions. 
 
An identical series of experiments were undertaken to assess the effects of 
the EP3 antagonist L798106 upon spontaneous and PGE2 stimulated 
contractions. In the first series, L798106 was added at increasing 
concentrations at 10nM, 100nM and 1000nM to spontaneously contracting 
myometrial strips at 15 minute intervals (Fig 5.4). A significant decrease in 
contractility at concentrations of 100nM (p=0.029) and 1000nM (p=0.020) 
was demonstrated.  
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Fig 5.4 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of L798106 added over 45 mins (n=7). A significant decrease in the 
total work done was demonstrated at concentrations of 100nM (p=0.029) and 
1000nM (p=0.020) respectively. 
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In the second series (Fig 5.5), pre-incubation of the lower segment 
myometrium with L798106 at 100nM caused a significant inhibition, but 
not a complete abolition, of spontaneous contractility (p=0.040) from thirty 
minutes into the onset of spontaneous contractions (t30). 
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A     B  
C     D  
 
         E  
     
Fig 5.5 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with a pre-incubation 
of 100nM of L798106 for 60 mins prior to the experiment commencing (n= 10). Pre-
incubation with L798106 caused a significant inhibition, but not a complete 
abolition, of spontaneous contractility from thirty minutes into the onset of 
spontaneous contractions (p=0.040). 
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In the third series of experiments involving L798106, 100nM of the EP3 
antagonist was added to the Kreb’s solution after the baseline period of 
spontaneous contractions had been established. Following which, at fifteen 
minute intervals, increasing concentrations of PGE2 was added at 
concentrations from 10
-10 
to 10
-6 
(Fig 5.6). 
 
At a concentration on 100nM, L798106 completely inhibited the dose 
dependent increase in contractility caused by PGE2 from 10
-9
 (p=0.028). 
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Fig 5.6 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) work done 
per contraction and (E) total work done in isolated myometrial strips taken from lower 
segment, non-labouring myometrium at term with increasing concentrations of PGE2 added 
over 75 mins to spontaneously contracting myometrial strips and to strips pre-incubated 
with a 100nM of L798106 (n=8). As previously demonstrated, PGE2 caused a dose 
dependent increase in contractility in lower segment myometrium at concentrations over  
10
-8
. The myometrial strips pre-incubated with L798106 significantly reduced the increase 
in total work done caused by PGE2 from concentrations of 10
-9
 (p=0.028). 
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5.3 Discussion of the role of EP1 and EP3 in human lower 
segment myometrial contractility in relation to their respective 
receptor antagonists. 
 
There are four PGE2 receptor subtypes (EP1, EP2, EP3, and EP4), each 
encoded by a separate gene (Astle et al 2005). EP1 and EP3 are excitatory 
(EP1 is coupled to Gαq and EP3 to Gαi) whereas EP2 and EP4 relax 
myometrial smooth muscle (both couple to Gαs) (Bastien L et al 1994). In 
the contractility experiments that I conducted, I concentrated on two novel 
EP1 and EP3 receptor antagonists, ZD6416 and L798106 respectively. 
Three series of experiments were undertaken to assess the effects of EP1 
antagonist ZD6416 upon spontaneous and PGE2 stimulated contractions. In 
the first series, ZD6416 added at increasing concentrations of 10, 100 and 
1000nM (i.e. the optimal concentration and one order of magnitude either 
side) to human, lower segment myometrial strips at fifteen minute intervals. 
The EP1 antagonist had no effect upon any individual aspect of contractility 
or upon total work done at any of the above concentrations (p=0.117, 
p=0.103, p=0119 respectively).  
 
In the second series of experiments involving ZD6416, 100nM was added to 
the Kreb’s solution at the start of the experiment. Pre-incubation of the 
myometrial strips with ZD6416 at 100nM did not inhibit any aspect of 
contractility including the total work done (p=0.104).  
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In the third series of experiments, 100nM of ZD6416 was added to the 
Kreb’s solution following the establishment of spontaneous contractions. 
Increasing concentrations of PGE2 was added from 10
-10 
to 10
-6
 at 15 minute 
intervals. As seen previously PGE2 caused a dose dependent increase in 
contractility at concentrations above 10
-8
, but there was no inhibitory effect 
of ZD6416 at this concentration of PGE2 (p=0.899). 
 
An identical series of experiments were undertaken to assess the effects of 
the EP3 antagonist L798106 on spontaneous and PGE2 stimulated 
contractions. L798106 was added at increasing concentrations of 10, 100 
and 1000nM (i.e. the optimal concentration and one order of magnitude 
either side) to spontaneously contracting myometrial strips at fifteen minute 
intervals. Unlike the EP1 antagonist, a significant decrease in contractility 
was demonstrated at concentrations of 100nM and 1000nM (p=0.029, 
p=0.020) respectively. 
 
In the second series of experiments involving L798106, pre-incubation of 
the myometrium at 100nM caused a significant inhibition, but not complete 
abolition, of spontaneous contractility (p=0.040), thirty minutes from the 
onset of spontaneous contractions. 
  
In the third series of experiments involving the EP3 antagonist, following 
the onset of spontaneous contractions, increasing concentrations of PGE2, 
were added to myometrium pre-incubated with a 100nM of L798106. The 
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EP3 antagonist successfully inhibited the dose dependent increase in 
contractility caused by PGE2 from concentrations of 10
-9
 (p=0.028).  
 
Two conclusions can therefore, be drawn from the preceding. Firstly, as the 
reduction in contractility caused by ASA (COX inhibitor) was more 
significant than that caused by either of the PGE2 receptor antagonists (EP1 
or EP3), it is likely that PGE2 plays a vital but not exclusive role in 
myometrial contractility. 
 
Secondly, given that L798106 demonstrated a significant reduction in 
myometrial contractility in comparison to ZD6416 (which demonstrated 
none); it is likely that the stimulating effect of PGE2 acts predominantly via 
the EP3 receptor. This provides evidence that the antagonism of the EP3 
receptor (rather than the EP1 receptor) may prove a suitable strategy in 
pharmacological tocolysis.  
 
The contractility data correlates with our expression studies on EP1 and EP3 
receptors in non-labouring, term, lower segment myometrium 
(unpublished).  It was demonstrated that EP1 becomes more nuclear 
localised in association with labour. This data is also consistent with that of 
Grigsby et al (2006), who found no regional differences in expression of 
EP1 at term or changes in association with labour and also found that 
expression of EP1 was localized to the nucleus in association with labour. 
Astle et al (2007) also showed that EP1 is nuclear localized, but they 
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identified a significant increase in EP1 expression at mRNA level in the 
lower segment in association with labour. However this increase, which was 
not demonstrated at a protein level was only of the order of 25% and no 
statistical correction was made for multiple testing. There is considerable 
inter-subject variation in expression levels of EP and we have concluded 
that, taken together, the available data suggests that there are no regional 
differences or significant changes in EP1 expression with the onset of 
labour, but that at the time of labour the receptor is localised to the nucleus. 
This suggests that the function of EP1 at term may be less to mediate 
intercellular signaling and more to mediate the nuclear effects of 
endogenous, intracellular PGE2. EP1 is therefore unlikely to be the principal 
receptor which mediates PGE2 stimulated myometrial contractions. 
 
Furthermore, at a protein level it was demonstrated that EP3 expression 
remains cytosolic in myometrium with the onset of labour, and like Grigsby 
et al (2006), but unlike Astle et al (2007) or Leonhardt et al (2003) we found 
significant expression in myocytes. We have concluded that the available 
data suggests that there are no regional differences or significant changes in 
EP3 expression with the onset of labour, but that EP3 is probably principally 
contractile in its action and remains cytosolic or on the cell membrane. EP3 
is therefore able to be liganded by extracellular, exogenous PGE2 and is 
likely to be the receptor which mediates PGE2 stimulated myometrial 
contractions. 
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6.1 The effect of FPA, a PGF2α antagonist upon spontaneous 
and PGF2α stimulated contractions. 
 
Increasing concentrations (100-1000nM) of a novel and selective FP 
antagonist (FPA) were added to isolated, lower segment myometrial strips. 
In comparison to the non-treated controls, FPA did not reduce the total work 
done by spontaneous contractions, even at the highest concentration of 
1000nM (10
-6
) (p=0.50).  
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A    B  
C    D  
                
             E  
 
Fig 6.1 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of FPA added over 45 mins (n=6). No significant difference in any of 
the parameters was demonstrated as illustrated by the total work done even at the 
highest concentration of 1000nM (10
-6
) (p=0.5). 
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In the next experiment, 10
-8
 PGF2 was added to spontaneously contracting 
strips of lower segment myometrium, following which increasing 
concentrations of FPA (10
-8
 to 10
-5
) were added at 15 minute intervals. The 
total work done by the myometrial strips which had the cumulative addition 
of FPA is decreased five-fold (Fig 6.2). This is in comparison to the PGF2  
pre-treated strips alone (p=0.044).  
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A       B  
C       D  
 
        E  
 
Fig 6.2 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of FPA (10
-8
 to 10
-5
) added over 45 mins  following an initial addition 
of 10
-8
 PGF2 (n=12). Increasing concentrations of FPA, significantly decreased the 
total work done by strips treated with PGF2 in comparison the PGF2 - treated 
strips alone and at concentrations of 10
-5
, total work done was reduced up to five-
fold (p=0.044).          
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6.2 Discussion of the effect of FPA, a novel PGF2α antagonist on 
contractility. 
 
The inhibition of FP has been proposed as a strategy to prevent preterm 
delivery. FP antagonists have been shown to inhibit contractions in isolated 
sheep and human myometrium (Olson DM et al 2003) and to open BKCa 
channels (Doheny HC et al 2007). FP antagonists also delay RU486 or LPS 
induced labour in mice, rat and sheep (Olson DM et al 2003, Chollet A et al 
2007). Therefore, I attempted to demonstrate the inhibition of human 
myometrial contractility with a novel and selective FP antagonist (FPA). 
Pre-incubation of the baths with concentrations up to 1uM (10
-6
) did not 
affect the total work done by spontaneous contractions in comparison to the 
non-treated controls (p=0.50).  
 
However, in myometrium pre-treated with a concentration of 10
-8
 of PGF2α, 
increasing concentrations of the FPA (from 10
-7
) decreased the contractility 
by five-fold. This was in comparison to PGF2α pre- treated myometrial 
strips alone (p=0.044).  
 
This demonstrates that FPA is able to block FP receptors, but does not 
inhibit spontaneous contractions. It is likely therefore, that PGF2α has no 
role in spontaneous myometrial contractility. This is in keeping with data 
previously published; i.e. PGE2 binds to myometrium 8-10 times more  than 
PGF2α (Hoffman HJ et al 1984), PGE2 is 8-10 times more potent than PGF2α 
in stimulating myometrial contractions (Martin et al 1995) and PGE2 binds 
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to its myometrial receptor with higher affinity than does PGF2α to its 
receptor (Giannopoulos G et al 1985). 
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7.1 The effect of combining the agonists, OT and PGE2 on 
spontaneously contracting lower segment myometrium. 
 
Having successfully demonstrated the effects of the EP1 and EP3 
antagonist, GSK were eager to investigate the effects of a novel OT 
antagonist, GW796679X in combination with the aforementioned EP3 
antagonist, L798106 on spontaneous contractions. The first step was to 
investigate the effect of combining OT and PGE2 on spontaneously 
contracting lower segment myometrium.  
 
To determine if OT and PGE2 combined produce a synergistic effect, first a 
concentration of 10
-8
 OT was added to spontaneously contracting 
myometrium. At fifteen minute intervals,  increasing concentrations of 
PGE2 from 10
-10
 to 10
-7
 were added to the organ baths. These strips 
containing both agonists were compared against myometrium with either 
agonist alone or spontaneously contracting controls (Fig 7.1).  
 
OT alone at a concentration of 10
-8
 increased contractility significantly in 
comparison to spontaneously contracting controls (p=0.001). A similar 
effect was demonstrated by PGE2 alone at a concentration of 10
-9
 (p=0.03). 
Furthermore, in combination, the PGE2 and OT significantly increased the 
total work done by the lower segment myometrium (p=0.035).  
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However, the combination of the two agonists caused a significant increase 
in total work done in comparison to the myometrium with the OT alone 
(p=0.041) but not by the PGE2 alone (p=0.32).
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A    B  
C    D  
 
               E  
      
Fig 7.1 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term with increasing 
concentrations of PGE2 added over 60 mins following an initial addition of 10
-8
 of 
OT; compared against PGE2 alone, OT alone and spontaneously contracting 
myometrium (n=8). Both the agonists individually, 10
-8
 OT (p=0.001), 10
-9
  PGE2 
(p=0.03) and in combination (p= 0.035)  significantly increased the total work done. 
Furthermore, the combined effect of the agonists on total work done was 
statistically greater than the strips with OT  alone (p=0.041) but not PGE2 alone 
(p=0.32). 
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7.2 The effect of combining the antagonists of OT and PGE2 on 
spontaneously contracting lower segment myometrium. 
 
To determine if there is a synergistic effect when combining antagonists, 
equimolar concentrations the OT antagonist, GW796679X and the EP3 
antagonist L798106, lower segment myometrial strips were pre-incubated 
with either the EP3 antagonist alone, the OT antagonist alone or a bath with 
both the OT and the EP3 antagonists in combination against control strips of 
spontaneously contracting myometrium.  
 
There was a statistically significant inhibition of contractility in the 
myometrial strips with L798106 alone at 30mins (p=0.029), but no 
inhibition by GW796679X alone (p=0.547), nor by a combination of both 
the antagonists (p=0.683).  
 
A synergistic effect of combining both an EP3 and an OT antagonist was 
not demonstrated in this experiment. 
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A      B  
C      D  
 
       E  
 
Fig 7.2 (A) Contraction rate, (B) peak tension, (C) duration per contraction, (D) 
work done per contraction and (E) total work done in isolated myometrial strips 
taken from lower segment, non-labouring myometrium at term pre-incubated with 
equimolar concentrations of L798106, GW796679X and of the two antagonists 
together for a period of 60 mins (n=10). There was a statistically significant 
reduction in total work done by L798106 alone at 30mins (p=0.029), but no 
inhibition by GW796679X alone (p=0.547), nor a combination of the two 
antagonists (p=0.683).  
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7.3 Discussing the effect of combining the agonists, OT and 
PGE2 and their respective antagonists on spontaneously 
contracting lower segment myometrium. 
 
Oxytocin is known to have a potent contractile activity on the pregnant 
uterus. In many animal models, OTR is regulated by changes in steroid 
hormone concentrations
 
(Soloff MS 1975). In humans, the lack of marked 
changes in oestrogen concentrations or progesterone withdrawal suggests 
that OTR has a more complex regulation
 
(Gimpl G et al 2001). Further 
relationships in the OTR system have been demonstrated, in particular with 
prostaglandins. Treatment with Naproxen, a prostaglandin-synthesis 
inhibitor, resulted in a dramatic decrease in OTR in the rat uterus at term. 
Administration of PGF2α restored the increase in OTR, implying the 
possibility of a positive feed- back loop between prostaglandins and OTR
 
(Chan WY 1980). 
 
In the final series of experiments, 10
-8 
OT increased total work done by 
sponataneously contracting lower segment myometrium significantly 
(p=0.001) as did 10
-9 
PGE2 (p=0.03). Unsurprisingly, a combination of OT 
and PGE2 demonstrated an increase in total work done on spontaneous 
contractions (p= 0.035). This combination of OT and PGE2 also increased 
the total work done significantly over myometrial strips with 10
-8
 OT alone 
(p= 0.041). This effect however, was not demonstrated in relation to 
myometrial strips with PGE2 alone (p=0.32). This experiment therefore, 
demonstrates that whilst PGE2 is a potent stimulator of spontaneous 
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contractions (more so than OT), no synergistic effect between PGE2 and OT 
was observed.  
 
The next step was to determine if a synergistic effect could be demonstrated 
between an OT antagonist and a PGE2 antagonist. Control strips of lower 
segment myometrium were set up in parallel with strips pre-incubated with 
either the EP3 antagonist alone, the OT antagonist alone and a bath with 
equimolar concentrations of both the OT antagonist and the EP3 antagonists 
in combination. There was a statistically significant inhibition of the 
myometrial strips by the EP3 antagonist alone at 30mins (p=0.029), but no 
inhibition by the OT antagonist alone (p=0.547), nor the combination of 
both antagonists (p=0.683). A synergistic effect of combining both an EP3 
and an OT antagonist was not demonstrated in this experiment. 
 
Given that 1) PGE2 is more powerful than OT in stimulating contractions 
and 2) the OT antagonist is not effective as the EP3 antagonist in inhibitng 
spontaneous contractions, these set of experiments support the argument in 
favour of a new tocolytic. 
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8.1 Discussion 
 
The primary function of the uterus during gestation is to harbour the 
growing fetus in a largely quiescent environment. Upon maturation of the 
fetus, the uterus must remodel itself sufficiently to generate forceful 
contractions during labour. During preterm delivery, the process of 
remodelling of the myometrium occurs early due to a number of causes, 
although the underlying basis of myometrial contraction remains the same. 
What is still unknown is to what degree various signalling factors and 
hormones affect myometrial contractility and certainly myometrial 
contractility in preterm labour. Due to the multi-factorial origin of preterm 
labour, treatment options generally target the inhibition of uterine 
contractility, rather than the underlying mechanisms of labour.  
 
Tocolytics, used in Europe for the last 30 years, are the backbone of 
treatment for the prevention of preterm labour. Tocolytic drugs are indicated 
to prolong pregnancy in women with acute risk of preterm birth; in some 
cases they are also administered for prophylaxis. The main rationale for use 
of these drugs is to delay delivery for at least 48 hours in order to allow 
treatment effect of corticosteroids or transfer of the pregnant woman to a 
specialised high-risk obstetric unit. Both actions have been show to 
markedly reduce neonatal morbidity and mortality (Husslein P et al 2003). 
As most randomised trials of tocolytic agents lack power to provide definite 
answers, and use delay in delivery as a surrogate endpoint for implied 
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improvements in neonatal outcome related to the administration of steroids, 
systemic reviews and meta-analyses have been conducted to more 
adequately study drug efficacy and safety. Several Cochrane reviews have 
been published that compare different tocolytic agents to each other or to 
placebo for women in preterm labour (King JF et al 2003, 2005, 
Anotayanonth S et al 2004, Whitworth M et al 2008).  
 
Many trials included maintenance treatment if and after contractions 
stopped. Some trials excluded women with ruptured membranes, but in 
others they were included. The most frequently evaluated agent was 
Ritodrine, which has predominantly β2- receptor effects; relaxing muscles 
in the uterus, arterioles and bronchi. Other tocolytics evaluated in these 
trials included Isoxuprine, Terbutaline, Magnesium sulphate, Indomethacin, 
Nifedipine and Atosiban. Overall tocolytics were associated with a 
reduction in the odds of delivery within 24 hours (OR 0.47; 95% CI 0.29-
0.77), 48 hours (OR 0.57; 95% CI 0.38-0.83) and seven days (OR 0.60; 95% 
CI 0.38-0.95). For beta agonists, Indomethacin, Nifedipine and Atosiban 
these effects were statistically significant, but not for Magnesium sulphate. 
However, there was no statistically significant reduction in births before 30 
weeks (OR 1.33; 95% CI 0.53-3.33), before 32 weeks (OR 0.81; 95% CI 
0.61-1.07) or 37 weeks of gestation (OR 0.17; 95% CI 0.02-1.62) (RCOG 
2006). The choice of tocolytic agent depends mainly on the availability 
following regulatory approval in the country, the drug efficacy and 
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effectiveness, the fetal and maternal safety profiles and the cost of 
treatment.  
 
Beta-mimetics have until the recent past, been the most commonly used 
tocolytic agent. It is certainly the most thoroughly evaluated, but as their 
mechanism of action is organ non-specific, they notoriously lead to  
numerous adverse events in multiple organ systems, which are largely 
cardiovascular in origin. Common adverse effects when beta-agonists are 
compared with no treatment or placebo include: palpitations (48% beta-
agonists vs. 5% control), tremor (39% vs. 4%), nausea (20% vs. 12%), 
headache (23% vs. 6%) and chest pain (10% vs. 1%) (Gyetvai K et al 2009). 
Rare but serious and potentially life threatening adverse effects have been 
reported following the use of beta-mimetics and there have been a small 
number of maternal deaths associated with the use of these drugs. 
Pulmonary oedema is a well documented complication, often associated 
with aggressive intravenous hydration. 
 
For the other tocolytic drugs, fewer types of adverse effects were reported, 
and they occurred less frequently (Gyetvai K et al 2009). With Magnesium 
sulphate, 7% discontinued treatment compared with none on placebo and 
none of the women allocated Indomethacin discontinued treatment 
compared to the control. For Atosiban, reported side effects were nausea 
(11% Atosiban vs. 5% placebo), vomiting (3% vs. 4%), headache (5% vs. 
7%), chest pain (1% vs. 4%) and dyspnoea (0.4% vs. 3%). 
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Systemic reviews of Nifedipine versus beta-mimetics have come to similar 
conclusions (Oei SG et al 1999, Tsatsaris V et al 2001). In both, there has 
been insufficient evidence for any conclusion, in particular with regards to 
the effect on neonatal mortality. Nifedipine, is however, associated with a 
greater chance of delaying labour for more than 48 hours (RR 1.13; 95% CI 
1.01-1.267), a lower risk of respiratory distress syndrome and admission to 
the neonatal unit. In addition, there were fewer maternal adverse effects 
with Nifedipine in comparison to Ritodrine (16% vs. 45%). Nifedipine has 
the advantage of oral administration and is economically sounder. 
 
Trials comparing Indomethacin with beta-agonists have shown not much 
difference in delay to delivery, but the former have fewer maternal side-
effects. However, the risk of premature closure of the ductus, renal and 
cerebral vasoconstriction and necrotising enterocolitis associated with a 
high dose and prolonged exposure of Indomethacin has led to concern and 
reluctance of its use in the clinical arena (Eronen M et al 1991, Norton ME 
et al 1993). 
 
Atosiban has been compared with at least three different beta-agonists; 
Ritodrine, Salbutamol and Terbutaline. The delay in delivery was not 
statistically significant at 48 hours (88% Atosiban vs. 89% beta-mimetics) 
(RR 0.99%; 95% CI 0.94-1.04) or at 7 days (80% vs. 77%) (RR 1.03%; 
95% CI 0.95 – 1.11) (The Worldwide Atosiban vs. Beta-agonists Study 
Group 2001). The side effect profile of Atosiban is significantly better than 
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beta-agonists, including chest pain (1% Atosiban vs. 5% beta-agonists), 
palpitations (2% vs. 16%), tachycardia (6% vs. 76%), hypotension (3% vs. 
6%), dyspnoea (0.3% vs. 7%), nausea (12% vs. 16%), vomiting (7% vs. 
22%) and headache (10% vs. 19%). The financial implications of using 
Atosiban are significantly greater however (£498.30 Atosiban vs. £0.15 
Nifedipine), assuming complete 48 hour treatment regardless of in-utero 
transfer (Siassakos D et al 2009). 
 
Therefore, if a decision is made to use a tocolytic agent, Ritodrine is no 
longer seems to be the drug of choice, given the most serious side effect is 
pulmonary oedema (Tan TC et al 2006). Atosiban does not affect the 
maternal heart rate or blood pressure (Goodwin TM et al 1994) and can be 
used safely in women with cardiac disease and diabetic women. When 
compared with placebo in a randomised trial (Romero R et al 2000), 
Atosiban resulted in lower birth weight and an increase in infant deaths. In 
this trial, there was an imbalance in randomisation that resulted in more 
women under 26 weeks gestation and fewer over 32 weeks assigned to the 
Atosiban group. Considering the significantly higher morbidity and 
mortality of babies born under 26 weeks, compared with those born over 26 
or 32 weeks, this imbalance can be argued to invalidate the findings of the 
study (Word RA et al 2003, 2005). Other randomised trials without such 
problems have not replicated these findings (Valenzuela GJ et al 2000). 
With regards to the long term follow-up of infants of mothers who received 
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Atosiban, it has been reported that developmental outcomes at 6, 12 and 24 
months are the same when compared to placebo (Papatsonis DN et al 2005). 
 
Nifedipine, unlike Atosiban, is not licensed for use as a tocolytic in the 
United Kingdom but given its relatively safe side-effect profile, its similar 
efficacy to Atosiban in delaying labour and definite cost effectiveness, it 
used in most obstetric units around the country. However, Nifedipine is 
contraindicated in women with cardiac disease and should be used in 
caution in women with diabetes. Cardiac failure has been reported with the 
use of Nifedipine (van Geijn HP et al 2005, Tan TC 2006) and in cases of 
maternal hypertension, where Nifedipine has been administered, there has 
been an association with a redistribution of fetal blood flow (Vojcek L et al 
1988). Brown MA et al (2002) have concluded that signs of fetal distress 
during fetal heart rate monitoring under these circumstances, have increased 
the rate of caesarean sections It is unknown whether these estimates can be 
applied to Nifedipine when used for tocolysis. 
 
In summary, it seems further evidence is required regarding the effects of 
both Nifedipine and Atosiban on more substantive outcomes such as 
neonatal mortality and morbidity, and on safety and long-term outcome for 
the child. It is not therefore unreasonable to consider the need for a new 
tocolytic.  
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Prostaglandins have long been postulated to play a role in the parturition 
process, mainly as their synthesis is dramatically increased in association 
with labour (Challis JR et al 2002, Olsen DM et al 2003). PGE2 in 
particular, is produced in large quantities by fetal membranes and possible 
roles include cervical ripening and the stimulation of uterine contractions 
(Challis JR et al 2000). Therefore, these desired effects lend them to use in 
obstetric practice. 
 
PGE2 exhibits a wide spectrum of physiological actions depending on the 
distribution and subtypes of EP receptors present (Breyer RM et al 2001). 
All four PGE2 receptors EP1-4 are present in human myometrial tissue 
during pregnancy, with distinct cellular patterns of expression being 
observed. Expression of EP1-4 receptor proteins are localised to vascular 
smooth muscle, vascular endothelium, glandular epithelium and decidual 
components of myometrial tissue. However, there is no consensus on 
whether there is a definite up-regulation of excitatory EP1 and EP3 or a 
down-regulation of EP2 or EP4 in labour. 
 
Functionally, EP1 and EP3 couple to G proteins, Gqα or Giα, and promote 
calcium influx or the inhibition of adenylate cylase respectively (Breyer RM 
et al 2001, Bos CL et al 2004). The stimulation of EP1 and EP3 would, 
therefore, result in the contraction of smooth muscle or an increase in 
inflammatory outputs. By contrast, EP2 and EP4 couple to Gsα to increase 
adenylyl cyclase activity and intracellular cAMP levels, leading to smooth 
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muscle relaxation and repressed expression of many inflammatory cytokines 
(Regan JW 2003).  
 
The only consistency in the literature is that both contractile and relaxatory 
EP receptors are simultaneously expressed in myometrial tissue. Thus, 
pharmacological studies using isolated myometrial strips and EP receptor 
agonists and antagonists is a more systematic approach to an understanding 
of the mechanisms by which PGE2 exerts its effects. This may lead to the 
pharmacological isolation of pro-labour actions of PGE2 from pro-
pregnancy actions and therefore to the improved management of obstetric 
patients from current management.  
 
In summary, our data demonstrates that the stretch of term human 
myometrium results in spontaneous contractions. The addition of ASA (a 
non-selective COX inhibitor) did not completely stop spontaneous 
contractility but reduced the total work done by up to five-fold. This 
indicates that prostaglandins play a significant role but not exclusive role in 
spontaneous contractility. The PGF2α antagonist did not have an inhibitory 
effect on spontaneous contractions, but only those contractions induced by 
the addition of PGF2α prior to the experiment. The EP1 antagonist similar to 
the PGF2α antagonist did not prove to be efficacious in inhibiting 
spontaneous contractions. The only significant reduction in total work done 
on spontaneously contracting lower segment myometrium was by the EP3 
antagonist.  
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Schild analysis has shown that each is a competitive antagonist devoid of 
agonist activity up to 10µM. The effective concentrations of each antagonist 
against their respective receptors were two orders of magnitude apart. A 
concentration of 100nM of each antagonist was calculated to ensure 
complete and specific inhibition of the relevant receptor. The EP3 receptor 
antagonist proved to cause significant reduction in spontaneous and PGE2 
induced contractility in term, non-labouring myometrium. The EP1 receptor 
antagonist, however, was not effective. These results therefore support the 
use of the EP3 antagonist in further clinical trials with regards to a new 
tocolytic compound. 
 
The advantages of targeting the EP3 antagonist alone, centre in that it would 
be more specific than knocking out PGE2 in general, and therefore 
potentially have fewer side effects. EP3 has been described in the literature 
as having other specific roles in the body. Inflammatory breast cancer (IBC) 
is the most aggressive subtype of locally advances breast cancer with the 
worst prognosis and shortest overall survival of any variant of this type of 
disease (Dawood S et al 2008). Current observations indicate that COX-2, 
EP3 and EP4 are all upregulated in IBC cells. Robertson FM et al (2010) 
have suggested that agents directly or indirectly targeting the signalling 
pathways of PGE2, EP3 or EP4 receptors may be important in inhibiting the 
aggressive phenotype of IBC. 
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However, in the gastrointestinal tract, PGE2 appears to play an important 
role in the modulating the mucosal integrity and various functions of the 
alimentary tract. In the duodenum, acid perfusion produces damage in 
animals lacking EP3 receptors (Takeuchi K 2010). As with all receptors in 
the body, there are very few that are exclusive to one organ system in the 
body. Ultimately one would have to work out a concentration of EP3 
antagonist to effectively knock off myometrial contractility whilst avoiding 
significant adverse effects globally in the body. 
 
Whilst there has been considerable literature concerning EP receptor 
function, expression and regulation in myometrium, there is little 
information on key issues such as cellular distribution of EP receptor 
expression and regulation in the uterine cervix. Several lines of evidence 
support a pivotal role for PGE2 in the regulation of the cervical ripening 
process. Firstly, PGE2 has been used clinically for at least 25 years to induce 
softening of the cervix successfully at term human pregnancy (Hughes EG 
et al 2001). Furthermore, COX-2 expression and PGE2 synthesis has been 
found to increase at the time of parturition in the rat and sheep cervix 
(Mitchell MD et al 1978, Dong YL et al 1996). In addition, PGE2 increases 
human cervical collagenolytic activity and GAG synthesis in the rat cervix 
(Cabrol D et al 1987), induces vasodilatation of human cervical arteries 
(Allen J et al 1988) and thus promotes subsequent oedema and leukocyte 
infiltration (Kelly RW 2002). 
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Schmitz T et al (2006) demonstrated the presence of all four EP receptor 
proteins in all tissue components of the ovine cervix: the endothelium and 
smooth muscle of the cervical blood vessels, the epithelium of the cervical 
canal, the circular and longitudinal muscle layers and the stroma. The 
localisation of the four EP receptors in blood vessels emphasises 
components of the vascular system as possible targets for PGE2. EP1 and 
EP3 receptors induce vasoconstriction, whereas EP2 and EP4 receptors 
cause vasodilatation (Wright DH et al 2001). Furthermore, the effects of 
steroid hormones on EP receptor expression in the cervix, demonstrate that 
whilst progesterone has no effect on any of the four EP receptors, estradiol 
significantly decreased EP1 and EP3 receptor protein expression in the 
blood vessel media of the cervix (Schmitz T et al 2006). 
 
Estradiol, by decreasing EP1 and EP3 receptor expression, would facilitate 
EP2 and EP4 receptor dependent vasodilator effects of PGE2 and therefore, 
promote cervical ripening. In other studies, EP4 receptor agonists have been 
shown to increase pregnant guinea-pig cervical compliance (Kanayama N et 
al 2004). In summary, by altering the balance of positive and negative 
influences on the cervix, reducing EP1 or EP3 receptor expression, may as a 
result increase the EP2 or EP4 receptor expression and cause cervical 
ripening. The regulation of PG synthesis and action occurring in the 
myometrium and cervix in association with labour appear to differ markedly 
between the two tissues, indicating tissue- specific roles for prostaglandins. 
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It may be that the classical approach of using tocolytics, with the sole 
purpose of arresting uterine contractions for the treatment of preterm labour 
is not the correct approach. Preterm labour should be viewed as a syndrome 
(Romero R et al 2006), where a number of pathological processes including 
intrauterine infection/ inflammation, uterine ischaemia, uterine over-
distension, abnormal allograft reaction, allergy, cervical insufficiency and 
hormonal disorders (progesterone related and corticotrophin-releasing factor 
related) may provide a trigger which stimulates the complex cascade 
culminating in uterine contractility, cervical dilatation and activation of the 
membranes/ decidua all of which initiate labour. Therefore, a multi-factorial 
approach in the diagnosis and management of preterm labour would appear 
to be the best solution in the treatment of preterm birth. 
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